119413-54-6 | Topotecan HCl

Packsize	Purity	Availability	Price	Discounted Price
10mg	98%	in stock	$8.00	$6.00
100mg	98%	in stock	$27.00	$19.00
250mg	98%	in stock	$51.00	$36.00
1g	98%	in stock	$136.00	$95.00
5g	98%	in stock	$529.00	$371.00
10g	98%	in stock	$924.00	$647.00

Description

• Catalog Number: AB52218
• Chemical Name: Topotecan HCl
• CAS Number: 119413-54-6
• Molecular Formula: C23H24ClN3O5
• Molecular Weight: 457.9068
• MDL Number: MFCD18452857
• SMILES: CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(c(c4cc3Cn1c2=O)CN(C)C)O.Cl

Computed Properties

• Complexity: 867
• Covalently-Bonded Unit Count: 2
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 32
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 3

Literature

• Chemical profiling of the genome with anti-cancer drugs defines target specificities.

  Nature chemical biology 20150701

• ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.

  Cancer research 20141201

• CEP-33779 antagonizes ATP-binding cassette subfamily B member 1 mediated multidrug resistance by inhibiting its transport function.

  Biochemical pharmacology 20140915

• Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines.

  Molecules (Basel, Switzerland) 20140217

• Theoretical and experimental studies of new modified isoflavonoids as potential inhibitors of topoisomerase I from Plasmodium falciparum.

  PloS one 20140101

• Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity.

  Cancer 20121115

• Anticancer activities of genistein-topotecan combination in prostate cancer cells.

  Journal of cellular and molecular medicine 20121101

• Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction.

  Leukemia & lymphoma 20121101

• Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis.

  Journal of pharmaceutical and biomedical analysis 20121101

• NK cell immunotherapy for high-risk neuroblastoma relapse after haploidentical HSCT.

  Pediatric blood & cancer 20121001

• Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species.

  Journal of pharmaceutical sciences 20121001

• Three-drug intra-arterial chemotherapy using simultaneous carboplatin, topotecan and melphalan for intraocular retinoblastoma: preliminary results.

  The British journal of ophthalmology 20121001

• The ubiquitin-conjugating enzyme E2-EPF is overexpressed in cervical cancer and associates with tumor growth.

  Oncology reports 20121001

• SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15.

  Oncogene 20120913

• The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.

  Molecular cancer therapeutics 20120901

• Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120901

• Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.

  Investigational new drugs 20120801

• Toxicity of weekly oral topotecan in relation to dosage for gynecologic malignancies: a phase I study.

  Anti-cancer drugs 20120801

• Complete remission after neoadjuvant chemotherapy of an advanced vulvar cancer patient: a case report.

  The journal of obstetrics and gynaecology research 20120701

• Topotecan and pegylated liposomal doxorubicin combination as palliative treatment in patients with pretreated advanced malignant pleural mesothelioma.

  International journal of clinical pharmacology and therapeutics 20120701

• Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20120701

• Structural spectroscopy and dynamics of inter- and intramolecular H-bonding interactions of topotecan, a potent anticancer drug, in organic solvents and in aqueous solution.

  The journal of physical chemistry. B 20120628

• Chemotherapy for brain metastases from small cell lung cancer.

  The Cochrane database of systematic reviews 20120613

• Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy.

  Journal of controlled release : official journal of the Controlled Release Society 20120610

• Loading profile of topotecan into polyvinyl alcohol microspheres (DC Bead™) over a 7-day period.

  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20120601

• Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493).

  Leukemia & lymphoma 20120601

• The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.

  Oncology reports 20120601

• Synthesis and biological evaluation of 7-alkenyl homocamptothecins as potent topoisomerase I inhibitors.

  Chemistry & biodiversity 20120601

• Live-cell monitoring of the glutathione-triggered release of the anticancer drug topotecan on gold nanoparticles in serum-containing media.

  Chemical communications (Cambridge, England) 20120504

• A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma.

  Oncotarget 20120501

• [Postmarketing surveillance study on the use of topotecan in small-cell lung cancer. Use of topotecan in a pneumology university department].

  Revue des maladies respiratoires 20120501

• Small cell lung cancer metastasizing to the colon in a colovesicular fistula in the setting of diverticulitis.

  The American surgeon 20120501

• Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20120411

• A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study.

  Gynecologic oncology 20120401

• Development of a combination drug-eluting bead: towards enhanced efficacy for locoregional tumour therapies.

  Anti-cancer drugs 20120401

• Chemotherapy-induced toxicity is highly heritable in Drosophila melanogaster.

  Pharmacogenetics and genomics 20120401

• Topotecan hydrochloride effects on retinal vessels in newborn rats.

  Histology and histopathology 20120401

• Topotecan plus carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a meta-analysis of randomized controlled trials.

  Journal of chemotherapy (Florence, Italy) 20120401

• Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors.

  Bioorganic & medicinal chemistry letters 20120315

• Identification of modulators of hair cell regeneration in the zebrafish lateral line.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20120307

• Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.

  Oncogene 20120301

• Phase 2 clinical trial of intrathecal topotecan in children with refractory leptomeningeal leukemia: a Children's Oncology Group trial (P9962).

  Pediatric blood & cancer 20120301

• An unusual case of congenital primitive neuroectodermal tumor with ocular metastasis.

  Journal of pediatric hematology/oncology 20120301

• Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.

  Gynecologic oncology 20120301

• In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.

  Drug metabolism and disposition: the biological fate of chemicals 20120301

• Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.

  The Journal of pharmacy and pharmacology 20120301

• First-line chemotherapy in epithelial ovarian cancer.

  Clinical obstetrics and gynecology 20120301

• ABCG2-overexpressing S1-M1-80 cell xenografts in nude mice keep original biochemistry and cell biological properties.

  Chinese journal of cancer 20120301

• Combined oral topotecan plus carboplatin in relapsed or advanced cervical cancer: a GINECO phase I-II trial.

  Anticancer research 20120301

• In vitro and in vivo evaluation of camptothecin nanosuspension: a novel formulation with high antitumor efficacy and low toxicity.

  International journal of pharmaceutics 20120227

• Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design.

  Cancer 20120215

• Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.

  The Journal of biological chemistry 20120203

• Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program.

  Pediatric blood & cancer 20120201

• Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO).

  Annals of oncology : official journal of the European Society for Medical Oncology 20120201

• Pharmacokinetic analysis of topotecan after superselective ophthalmic artery infusion and periocular administration in a porcine model.

  Retina (Philadelphia, Pa.) 20120201

• A novel method to load topotecan into liposomes driven by a transmembrane NH₄EDTA gradient.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20120201

• Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma.

  Biomaterials 20120201

• Effect of PI3K/Akt pathway inhibition-mediated G1 arrest on chemosensitization in ovarian cancer cells.

  Anticancer research 20120201

• Success of intra-arterial chemotherapy (chemosurgery) for retinoblastoma: effect of orbitovascular anatomy.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20120201

• Silenced genes turned on to treat Angelman's syndrome.

  Lab animal 20120120

• Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons.

  Nature 20120112

• Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin/topotecan, mitoxantrone, or etoposide.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20120101

• Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells.

  PloS one 20120101

• Synthetic lethal screen identifies NF-κB as a target for combination therapy with topotecan for patients with neuroblastoma.

  BMC cancer 20120101

• Overcoming multidrug resistance via photodestruction of ABCG2-rich extracellular vesicles sequestering photosensitive chemotherapeutics.

  PloS one 20120101

• Ophthalmic artery chemosurgery for less advanced intraocular retinoblastoma: five year review.

  PloS one 20120101

• A small molecule SMAC mimic LBW242 potentiates TRAIL- and anticancer drug-mediated cell death of ovarian cancer cells.

  PloS one 20120101

• [Studies by means of 1H NMR spectroscopy of complex formation of aromatic biologically active compounds with antibiotic topotecan].

  Ukrains'kyi biokhimichnyi zhurnal (1999 ) 20120101

• Deletion of HIF-1α partially rescues the abnormal hyaloid vascular system in Cited2 conditional knockout mouse eyes.

  Molecular vision 20120101

• Weekly topotecan for recurrent small cell lung cancer - a retrospective Anatolian Medical Oncology Group study.

  Asian Pacific journal of cancer prevention : APJCP 20120101

• The inhibition of autophagy sensitises colon cancer cells with wild-type p53 but not mutant p53 to topotecan treatment.

  PloS one 20120101

• EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.

  PloS one 20120101

• Neurodevelopmental disorders. New hope for a devastating neurological disorder.

  Science (New York, N.Y.) 20111223

• Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20111215

• Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study.

  Investigational new drugs 20111201

• A phase I study of topotecan and gemcitabine in advanced solid tumors.

  Investigational new drugs 20111201

• High antimetastatic efficacy of MEN4901/T-0128, a novel camptothecin carboxymethyldextran conjugate.

  The Journal of surgical research 20111201

• A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma.

  International journal of clinical oncology 20111201

• Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan.

  Neurosurgery 20111201

• Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.

  Journal of neuro-oncology 20111201

• Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts.

  Neuro-oncology 20111201

• Pharmacokinetic evaluation of gemcitabine hydrochloride for the treatment of cervical cancer.

  Expert opinion on drug metabolism & toxicology 20111201

• Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.

  Gynecologic oncology 20111201

• Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.

  Cell cycle (Georgetown, Tex.) 20111201

• Effect of topotecan as second-line chemotherapy for small cell lung cancer patients with interstitial lung disease.

  Journal of chemotherapy (Florence, Italy) 20111201

• Enhancement of the fraction of the active form of an antitumor drug topotecan via an injectable hydrogel.

  Journal of controlled release : official journal of the Controlled Release Society 20111130

• Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111120

• Determining the best dose for the individual patient.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111120

• MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment.

  European journal of pharmacology 20111116

• Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20111101

• Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers.

  Gynecologic oncology 20111101

• [Molecular determinants of response to topoisomerase I inhibitors].

  Bulletin du cancer 20111101

• A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.

  Lung cancer (Amsterdam, Netherlands) 20111001

• Chloroquine enhances the cytotoxicity of topotecan by inhibiting autophagy in lung cancer cells.

  Chinese journal of cancer 20111001

• Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer.

  Anticancer research 20111001

• Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20110901

• Enhanced antitumor activity of low-dose continuous administration schedules of topotecan in prostate cancer.

  Cancer biology & therapy 20110901

• Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110901

• Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.

  Cancer research 20110901

• Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study.

  Cancer 20110815

• Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer.

  Cancer chemotherapy and pharmacology 20110801

• Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110801

• A prospective phase II study of topotecan (Hycamtin®) and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer.

  Gynecologic oncology 20110801

• Can weekly topotecan substitute for a multi-day regimen in the treatment of ovarian cancer? Sadly, 10 years later the answer remains unknown.

  Gynecologic oncology 20110801

• Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part II.

  Archivum immunologiae et therapiae experimentalis 20110801

• Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110801

• Quantification of the interceptor action of caffeine on the in vitro biological effect of the anti-tumour agent topotecan.

  European biophysics journal : EBJ 20110801

• Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump.

  Neuro-oncology 20110801

• Topotecan and ifosfamide systemic chemotherapy for CNS involvement of solid tumors.

  Journal of neuro-oncology 20110701

• Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma.

  Gynecologic oncology 20110701

• Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study.

  Gynecologic oncology 20110701

• Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.

  Gynecologic oncology 20110701

• Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography.

  Nuclear medicine and biology 20110701

• Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.

  Lung cancer (Amsterdam, Netherlands) 20110601

• [Small cell neuroendocrine carcinoma of the bladder: A case report and review of the literature].

  Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique 20110601

• Convection-enhanced delivery of topotecan into a PDGF-driven model of glioblastoma prolongs survival and ablates both tumor-initiating cells and recruited glial progenitors.

  Cancer research 20110601

• Periocular topotecan for intraocular retinoblastoma.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20110601

• Topotecan for relapsed small cell lung cancer: a systematic review and economic evaluation.

  Cancer treatment reviews 20110501

• Electrochemical detection of anticancer drug topotecan using nano-acetylene black film.

  Colloids and surfaces. B, Biointerfaces 20110501

• A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer.

  Clinical lung cancer 20110501

• The solvolysis of topotecan in alcohols and acetic anhydride.

  Bioorganic & medicinal chemistry letters 20110415

• Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.

  Molecular pharmaceutics 20110404

• Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma.

  Bone marrow transplantation 20110401

• Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports.

  Brain tumor pathology 20110401

• The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic factor-mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan.

  Cancer 20110315

• A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma.

  Japanese journal of clinical oncology 20110301

• High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan.

  Pediatric blood & cancer 20110301

• Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma.

  European journal of cancer (Oxford, England : 1990) 20110301

• A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q).

  Gynecologic oncology 20110301

• Multifaceted chemotherapy for trilateral retinoblastoma.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20110301

• Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer.

  Archives of gynecology and obstetrics 20110201

• Phase I study of topotecan and cisplatin in patients with small cell lung cancer.

  Japanese journal of clinical oncology 20110201

• Physiologically based pharmacokinetic model for topotecan in mice.

  Journal of pharmacokinetics and pharmacodynamics 20110201

• Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress.

  Proceedings of the National Academy of Sciences of the United States of America 20110125

• Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110120

• Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma.

  Cancer 20110115

• Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells.

  Biochemical pharmacology 20110115

• Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110110

• Antiangiogenic combination therapy after local radiotherapy with topotecan radiosensitizer improved quality of life for children with inoperable brainstem gliomas.

  Acta paediatrica (Oslo, Norway : 1992) 20110101

• Second high-dose chemotherapy intensification followed by hematopoietic stem cell transplantation applying a novel high-dose topotecan-based regimen in an adult Wilms' tumor patient: case report.

  Anti-cancer drugs 20110101

• An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer.

  Gynecologic oncology 20110101

• A phase 1 study of nifurtimox in patients with relapsed/refractory neuroblastoma.

  Journal of pediatric hematology/oncology 20110101

• A phase II study of metronomic oral topotecan for recurrent childhood brain tumors.

  Pediatric blood & cancer 20110101

• Antitumor effect of suberoylanilide hydroxamic acid and topotecan in renal cancer cells.

  Oncology research 20110101

• Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy.

  Journal of translational medicine 20110101

• Long-term topotecan therapy in recurrent or persistent ovarian cancer.

  European journal of gynaecological oncology 20110101

• A novel inhibitor of hypoxia-inducible factor-1α P3155 also modulates PI3K pathway and inhibits growth of prostate cancer cells.

  BMC cancer 20110101

• Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer.

  Oncology 20110101

• Assessment of anti-cytogenotoxic effects of quercetin in animals treated with topotecan.

  Oxidative medicine and cellular longevity 20110101

• Chemoresistance testing of human ovarian cancer cells and its in vitro model.

  Toxicology in vitro : an international journal published in association with BIBRA 20101201

• Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study.

  Gynecologic oncology 20101201

• Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.

  Cancer biology & therapy 20101201

• Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons.

  Molecular cancer therapeutics 20101201

• Laser induced fluorescence and photochemical derivatization for trace determination of camptothecin.

  Talanta 20101115

• A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.

  Cancer chemotherapy and pharmacology 20101101

• Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study.

  European journal of cancer (Oxford, England : 1990) 20101101

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• Double high-dose chemotherapy and stem cell transplantation in adult Wilms' tumor.

  Future oncology (London, England) 20101101

• [Application of ATP-tumor chemosensitivity assay in recurrent epithelial ovarian cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20101101

• Nigericin-mediated liposome loading of topotecan: is nigericin a potential drug release regulator?

  International journal of pharmaceutics 20101031

• Another confirmation of the inactivity of topotecan in ovarian cancer.

  Journal of the National Cancer Institute 20101020

• Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.

  Journal of the National Cancer Institute 20101020

• Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors.

  Cancer chemotherapy and pharmacology 20101001

• Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours.

  European journal of cancer (Oxford, England : 1990) 20101001

• Therapy of small cell lung cancer with emphasis on oral topotecan.

  Lung cancer (Amsterdam, Netherlands) 20101001

• Sequence-dependent hematologic side effects of topotecan and cisplatin in persistent or recurrent cervical cancer.

  Gynecologic oncology 20101001

• Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20101001

• Combining cytotoxic and targeted therapies for lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20101001

• Optimization of vincristine-topotecan combination--paving the way for improved chemotherapy regimens by nanoliposomes.

  Journal of controlled release : official journal of the Controlled Release Society 20100915

• Comparison of DC Bead-irinotecan and DC Bead-topotecan drug eluting beads for use in locoregional drug delivery to treat pancreatic cancer.

  Journal of materials science. Materials in medicine 20100901

• A phase I study of weekly topotecan in combination with pemetrexed in patients with advanced malignancies.

  The oncologist 20100901

• Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy.

  British journal of cancer 20100824

• Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100820

• Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100820

• Chrysin blocks topotecan-induced apoptosis in Caco-2 cells in spite of inhibition of ABC-transporters.

  Biochemical pharmacology 20100815

• Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study.

  American journal of clinical oncology 20100801

• Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery).

  Ophthalmology 20100801

• Altered phospholipid transfer protein gene expression and serum lipid profile by topotecan.

  Biochemical pharmacology 20100801

• Topotecan and etoposide combination to test neuroblastoma in pediatric preclinical testing program.

  Pediatric blood & cancer 20100801

• Topotecan dynamics, tautomerism and reactivity--1H/13C NMR and ESI MS study.

  Magnetic resonance in chemistry : MRC 20100801

• Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2.

  Assay and drug development technologies 20100801

• [Effect of cisplatin, topotecan, daunorubicin and hydroxyurea on human mesenchymal stem cells].

  Zhongguo shi yan xue ye xue za zhi 20100801

• Experiment on the factors for enhancing the susceptibility of cancer cells to chemotherapeutic drug by ultrasound microbubbles.

  Journal of drug targeting 20100701

• Pharmacokinetic analysis of topotecan after intra-vitreal injection. Implications for retinoblastoma treatment.

  Experimental eye research 20100701

• Phase I and pharmacologic study of weekly bolus topotecan for advanced non-small-cell lung cancer.

  Clinical lung cancer 20100701

• Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer.

  Anticancer research 20100701

• Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma.

  Cancer 20100615

• Improved extrapolation of hepatobiliary clearance from in vitro sandwich cultured rat hepatocytes through absolute quantification of hepatobiliary transporters.

  Molecular pharmaceutics 20100607

• A phase I-II trial of weekly topotecan in the treatment of recurrent cervical carcinoma.

  Medical oncology (Northwood, London, England) 20100601

• Review role of topotecan in gynaecological cancers: current indications and perspectives.

  Critical reviews in oncology/hematology 20100601

• A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies.

  Gynecologic oncology 20100601

• Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas.

  Cancer research 20100601

• A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100601

• Solvent effects on the valence UV-vis absorption spectra of topotecan anticancer drug in aqueous solution at room temperature: a nanoseconds time-scale TD-DFT/MD computational study.

  The journal of physical chemistry. B 20100527

• Initial testing of topotecan by the pediatric preclinical testing program.

  Pediatric blood & cancer 20100501

• Tumorigenic role of podoplanin in esophageal squamous-cell carcinoma.

  Annals of surgical oncology 20100501

• Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.

  Pediatric blood & cancer 20100501

• Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix.

  Health technology assessment (Winchester, England) 20100501

• [Hematological toxicity of some combined chemotherapy schemes involving aranoza].

  Eksperimental'naia i klinicheskaia farmakologiia 20100501

• Topotecan in second-line treatment of small-cell lung cancer--how it works in our daily clinical practice?

  Current drug safety 20100401

• Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.

  Cancer chemotherapy and pharmacology 20100401

• Episcleral implants for topotecan delivery to the posterior segment of the eye.

  Investigative ophthalmology & visual science 20100401

• Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous system.

  Pediatric blood & cancer 20100401

• Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.

  Molecular cancer therapeutics 20100401

• Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.

  Molecular cancer therapeutics 20100401

• [Immediate versus delayed topotecan after first-line therapy in small cell lung cancer].

  Zhongguo fei ai za zhi = Chinese journal of lung cancer 20100320

• Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.

  Bone marrow transplantation 20100301

• A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer.

  Journal of clinical pharmacology 20100301

• The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.

  European journal of haematology 20100301

• A semi-physiological-based pharmacokinetic/pharmacodynamic model to describe the effects of topotecan on b-lymphocyte lineage cells.

  Pharmaceutical research 20100301

• Quantification of topotecan by liquid chromatography-mass spectrometry (LC-MS). Application to intestinal transport using rat everted gut sacs.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100301

• Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100301

• Bilateral superselective ophthalmic artery chemotherapy for bilateral retinoblastoma: tandem therapy.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20100301

• The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation.

  Health technology assessment (Winchester, England) 20100301

• Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma.

  Biochemical pharmacology 20100215

• Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.

  Cancer research 20100215

• Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study.

  Anti-cancer drugs 20100201

• Inhibition of glutathione-S-transferase as a treatment strategy for multidrug resistance in childhood rhabdomyosarcoma.

  International journal of oncology 20100201

• Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience.

  The journal of obstetrics and gynaecology research 20100201

• The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma.

  Clinical advances in hematology & oncology : H&O 20100201

• Erybraedin C, a natural compound from the plant Bituminaria bituminosa, inhibits both the cleavage and religation activities of human topoisomerase I.

  The Biochemical journal 20100115

• Development of a highly stable and targetable nanoliposomal formulation of topotecan.

  Journal of controlled release : official journal of the Controlled Release Society 20100104

• Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group.

  British journal of haematology 20100101

• Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3-mediated Bid cleavage.

  The Journal of pharmacology and experimental therapeutics 20100101

• Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response.

  Pediatric blood & cancer 20100101

• Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.

  Anti-cancer drugs 20100101

• Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study.

  Gynecologic oncology 20100101

• Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia.

  Cancer 20100101

• PIDDosome expression and the role of caspase-2 activation for chemotherapy-induced apoptosis in RCCs.

  Cellular oncology : the official journal of the International Society for Cellular Oncology 20100101

• [Effect of topotecan as a second line treatment in small cell lung cancer patients. Preliminary report].

  Pneumonologia i alergologia polska 20100101

• Structural and dynamical effects induced by the anticancer drug topotecan on the human topoisomerase I - DNA complex.

  PloS one 20100101

• Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer.

  BMC cancer 20100101

• Targeting the oncogenic protein beta-catenin to enhance chemotherapy outcome against solid human cancers.

  Molecular cancer 20100101

• AP-1-Dependent miR-21 expression contributes to chemoresistance in cancer stem cell-like SP cells.

  Oncology research 20100101

• Idiopathic hyperammonemia after chemotherapy with vinorelbine, topotecan, and cisplatin in a patient with acute lymphocytic leukemia.

  Hematology/oncology and stem cell therapy 20100101

• Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study.

  Gynecologic oncology 20091201

• Antitumor activity of delimotecan against human metastatic melanoma: pharmacokinetics and molecular determinants.

  International journal of cancer 20091115

• Topotecan-carboplatin-etoposide combination as 1st line treatment in patients with small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20091101

• Venous thromboembolism in recurrent ovarian cancer-patients: A systematic evaluation of the North-Eastern German Society of Gynaecologic Oncology Ovarian Cancer Study Group (NOGGO).

  Thrombosis research 20091101

• Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience.

  Journal of neuro-oncology 20091101

• A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study.

  Gynecologic oncology 20091101

• Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091101

• ABCG2-associated resistance to Hoechst 33342 and topotecan in a murine cell model with constitutive expression of side population characteristics.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20091101

• Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.

  Molecular cancer therapeutics 20091101

• Differential microRNA-34a expression and tumor suppressor function in retinoblastoma cells.

  Investigative ophthalmology & visual science 20091001

• Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091001

• A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation.

  International journal of radiation oncology, biology, physics 20091001

• Chemotherapy: Topotecan or treosulfan--that is the question.

  Nature reviews. Clinical oncology 20091001

• New advances in the second-line treatment of small cell lung cancer.

  The oncologist 20091001

• [Clinical study on regimen cyclophosphamide, Ara-C and topotecan (CAT) in treatment of patients with refractory or relapsed acute myelogenous leukemia].

  Zhongguo shi yan xue ye xue za zhi 20091001

• [Medical management of primary central nervous system lymphoma refractory or resistant to standard of care treatment].

  Brain and nerve = Shinkei kenkyu no shinpo 20091001

• Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.

  European journal of cancer (Oxford, England : 1990) 20090901

• Effects of concurrent topotecan and radiation on 6-month progression-free survival in the primary treatment of glioblastoma multiforme.

  International journal of radiation oncology, biology, physics 20090901

• Weekly topotecan and daily thalidomide in patients with recurrent epithelial ovarian cancer: a report of 2 cases.

  The Journal of reproductive medicine 20090901

• The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.

  Cancer letters 20090828

• Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma.

  Cancer biology & therapy 20090815

• HIF-1alpha modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines.

  Journal of cancer research and clinical oncology 20090801

• Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).

  Gynecologic oncology 20090801

• Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study.

  Gynecologic oncology 20090801

• 7-Cycloalkylcamptothecin derivatives: Preparation and biological evaluation.

  Bioorganic & medicinal chemistry letters 20090801

• Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy.

  Journal of pediatric hematology/oncology 20090801

• [Effect of topotecan on expression of aquaporin protein 5 and nuclear factor-kappaB in ovarian cancer SKOV3 cells].

  Ai zheng = Aizheng = Chinese journal of cancer 20090801

• [Effect of topotecan on MAGE gene expression of HPB-AM cells].

  Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 20090801

• Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.

  Cancer research 20090715

• Application of a highly specific and sensitive fluorescent HPLC method for topotecan lactone in whole blood.

  Biomedical chromatography : BMC 20090701

• Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090701

• Blasting neuroblastoma using optimal control of chemotherapy.

  Mathematical biosciences and engineering : MBE 20090701

• Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.

  Molecular cancer therapeutics 20090701

• Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.

  Cancer letters 20090628

• Salvage therapy with topotecan in heavily pretreated ovarian cancer patients.

  Journal of cancer research and clinical oncology 20090601

• Topotecan in combination with radiotherapy in unresectable glioblastoma: a phase 2 study.

  Journal of neuro-oncology 20090601

• A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers.

  Gynecologic oncology 20090601

• Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy.

  The Journal of pharmacology and experimental therapeutics 20090501

• MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy.

  Gynecologic oncology 20090501

• The combination topotecan, temozolomide and dexamethasone associated with radiotherapy as treatment of central nervous system myeloma relapse.

  International journal of hematology 20090501

• A phase I study of topotecan plus carboplatin for relapsed SCLC: WJTOG trial.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20090501

• Topotecan inhibits cancer cell migration by down-regulation of chemokine CC motif receptor 7 and matrix metalloproteinases.

  Acta pharmacologica Sinica 20090501

• Topotecan-induced long-term remission of an advanced endometrial cancer after treatment with cisplatinum, an anthracycline and paclitaxel.

  Anticancer research 20090501

• A phase I study of periocular topotecan in children with intraocular retinoblastoma.

  Investigative ophthalmology & visual science 20090401

• Lack of stability of topotecan in heart tissue homogenates: is it an analytical dilemma or a real phenomenon?

  Biomedical chromatography : BMC 20090401

• Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial.

  Gynecologic oncology 20090401

• NDRG1 is down-regulated in the early apoptotic event induced by camptothecin analogs: the potential role in proteolytic activation of PKC delta and apoptosis.

  Proteomics 20090401

• Three-day topotecan schedule in heavily pretreated recurrent ovarian cancer patients.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20090401

• EGFR inhibition using gefitinib is not active in neuroblastoma cell lines.

  Anticancer research 20090401

• Triple cytotoxic therapy for advanced ovarian cancer: a failed application, not a failed strategy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090320

• Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090320

• Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected stage IV non-small-lung cancer.

  International journal of radiation oncology, biology, physics 20090301

• Modulation of the physicochemical state of interior agents to prepare controlled release liposomes.

  Colloids and surfaces. B, Biointerfaces 20090301

• Molecular cytogenetic evaluation of the mechanism of micronuclei formation induced by camptothecin, topotecan, and irinotecan.

  Environmental and molecular mutagenesis 20090301

• Current role and future aspects of topotecan in relapsed ovarian cancer.

  Current medical research and opinion 20090301

• Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors.

  International journal of clinical pharmacology and therapeutics 20090301

• Semisynthesis, biological activity, and molecular modeling studies of C-ring-modified camptothecins.

  Journal of medicinal chemistry 20090226

• Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090215

• Topotecan enhances immune clearance of gliomas.

  Cancer immunology, immunotherapy : CII 20090201

• Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors.

  American journal of clinical oncology 20090201

• [Effect of different chemotherapy regimens for concurrent chemoradiotherapy on locally advanced non-small cell lung cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20090201

• A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer.

  British journal of cancer 20090127

• Efficacy of topotecan plus vincristine and doxorubicin in children with recurrent/refractory rhabdomyosarcoma.

  Medical oncology (Northwood, London, England) 20090101

• A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.

  Gynecologic oncology 20090101

• Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer.

  Medical oncology (Northwood, London, England) 20090101

• Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803).

  Cancer 20090101

• Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals.

  Molecular pharmaceutics 20090101

• Cytometric analysis of DNA damage: phosphorylation of histone H2AX as a marker of DNA double-strand breaks (DSBs).

  Methods in molecular biology (Clifton, N.J.) 20090101

• Functional expression of a DNA-topoisomerase IB from Cryptosporidium parvum.

  Journal of biomedicine & biotechnology 20090101

• Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group.

  Pediatric blood & cancer 20081201

• WRN protects against topo I but not topo II inhibitors by preventing DNA break formation.

  DNA repair 20081201

• Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.

  Gynecologic oncology 20081201

• Glutamate regulates the activity of topoisomerase I in mouse cerebellum.

  Molecular neurobiology 20081201

• Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081201

• Management of small-cell lung cancer: incremental changes but hope for the future.

  Oncology (Williston Park, N.Y.) 20081130

• Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081120

• Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081115

• Antitumor efficacy testing in rodents.

  Journal of the National Cancer Institute 20081105

• A modified surgical procedure for microdialysis probe implantation in the lateral ventricle of a FVB mouse.

  Journal of pharmaceutical sciences 20081101

• Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer.

  Cancer chemotherapy and pharmacology 20081101

• Topotecan distribution in an anephric infant with therapy-resistant bilateral Wilms tumor with a novel germline WT1 gene mutation.

  Cancer chemotherapy and pharmacology 20081101

• Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells.

  Pharmaceutical research 20081101

• Chemotherapy for recurrent cervical cancer.

  Cancer treatment reviews 20081101

• Interspecies scaling of a camptothecin analogue: human predictions for intravenous topotecan using animal data.

  Xenobiotica; the fate of foreign compounds in biological systems 20081101

• [A case of stage IV breast cancer in which a long-term no change state (NC) was attained by a combination of S-1 and TAM following AC-T as a primary systemic therapy (PST)].

  Gan to kagaku ryoho. Cancer & chemotherapy 20081101

• Future research directions for the treatment of AML.

  Clinical advances in hematology & oncology : H&O 20081101

• Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions.

  Pharmaceutical research 20081001

• Paclitaxel, topotecan, and carboplatin in metastatic endometrial cancinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.

  Gynecologic oncology 20081001

• Phosphorylation of p53 on Ser15 during cell cycle caused by Topo I and Topo II inhibitors in relation to ATM and Chk2 activation.

  Cell cycle (Georgetown, Tex.) 20081001

• Experimental treatment of neuroblastoma using [131I]meta-iodobenzylguanidine and topotecan in combination.

  The British journal of radiology 20081001

• Symptom assessment in relapsed small cell lung cancer: cross-validation of the patient symptom assessment in lung cancer instrument.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20081001

• A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.

  American journal of clinical oncology 20081001

• Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors.

  Molecular cancer therapeutics 20081001

• [Down-regulation of TopI by RNA interference reduces the drug-sensitivity of small cell lung cancer cell lines to topotecan].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20081001

• Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays.

  Gynecologic oncology 20080901

• Trilateral retinoblastoma with pituitary-hypothalamic dysfunction.

  Ophthalmic genetics 20080901

• Long-term survival of a patient with small cell lung cancer after nine lines of chemotherapy and radiation.

  Onkologie 20080901

• AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.

  Molecular cancer therapeutics 20080901

• Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study.

  Cancer chemotherapy and pharmacology 20080801

• The feasibility of using topotecan, vinorelbine, thiotepa and gemcitabine (TVTG) in adult patients with relapsed/refractory acute lymphoblastic leukaemia/lymphoma.

  Leukemia 20080801

• Topotecan treatment and its toxic effects on hematologic parameters and trace elements.

  Biological trace element research 20080801

• Phase 2 study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal carcinoma.

  Cancer 20080801

• Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium.

  Gynecologic oncology 20080801

• Phase II study of a 3-day schedule with topotecan and cisplatin in patients with previously untreated small cell lung cancer and extensive disease.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080801

• Optimizing MIBG therapy of neuroendocrine tumors: preclinical evidence of dose maximization and synergy.

  Nuclear medicine and biology 20080801

• [Effects of CPUY013, a novel Topo I inhibitor, on human gastric adenocarcinoma BGC823 cells in vitro and in vivo].

  Yao xue xue bao = Acta pharmaceutica Sinica 20080801

• Novel hexacyclic camptothecin derivatives. Part 1: synthesis and cytotoxicity of camptothecins with an A-ring fused 1,3-oxazine ring.

  Bioorganic & medicinal chemistry letters 20080715

• Central neurocytoma responsive to topotecan, ifosfamide, carboplatin.

  Pediatric blood & cancer 20080701

• Intrathecal chemotherapy delivered by a lumbar-thecal catheter in metastatic medulloblastoma: a case illustration.

  Acta neurochirurgica 20080701

• Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080701

• Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha.

  Molecular cancer therapeutics 20080701

• Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968.

  Molecular cancer therapeutics 20080701

• Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan.

  Investigational new drugs 20080601

• Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers.

  Gynecologic oncology 20080601

• Kinetics of histone H2AX phosphorylation and Chk2 activation in A549 cells treated with topotecan and mitoxantrone in relation to the cell cycle phase.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20080601

• Exploration of the intercellular heterogeneity of topotecan uptake into human breast cancer cells through compartmental modelling.

  Mathematical biosciences 20080601

• Prolonged survival with continuous infusion topotecan: a report of 2 cases.

  Journal of pediatric hematology/oncology 20080601

• The expression of Bcl-XL, Bcl-XS and p27Kip1 in topotecan-induced apoptosis in hepatoblastoma HepG2 cell line.

  Cancer investigation 20080601

• [Recent progress in the study on antitumor drugs targeting hypoxia-inducible factor-1].

  Yao xue xue bao = Acta pharmaceutica Sinica 20080601

• Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trial.

  Lung cancer (Amsterdam, Netherlands) 20080501

• Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.

  Cancer 20080501

• Topoisomerase I inhibitors for the treatment of brain tumors.

  Expert review of anticancer therapy 20080501

• Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.

  Expert review of anticancer therapy 20080501

• A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer.

  Clinical lung cancer 20080501

• Topotecan for ovarian cancer.

  The Cochrane database of systematic reviews 20080416

• The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.

  International journal of pharmaceutics 20080402

• Symptom burden after autologous stem cell transplantation for multiple myeloma.

  Cancer 20080401

• Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis.

  Current medical research and opinion 20080401

• A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies.

  Neuro-oncology 20080401

• Combination of metronomic gimatecan and CpG-oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft.

  Cancer biology & therapy 20080401

• Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.

  Leukemia & lymphoma 20080401

• Freeze drying of double emulsions to prepare topotecan-entrapping liposomes featuring controlled release.

  Drug development and industrial pharmacy 20080401

• Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia.

  Anti-cancer drugs 20080401

• Quantifying synergism/antagonism using nonlinear mixed-effects modeling: a simulation study.

  Statistics in medicine 20080330

• Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma.

  Pediatric blood & cancer 20080301

• Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study.

  Gynecologic oncology 20080301

• [Therapeutic and adverse effects of topotecan combined with cisplatin for treatment of advanced squamous cell lung cancer and head and neck cancer].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20080301

• Construction of optimized bispecific antibodies for selective activation of the death receptor CD95.

  Cancer research 20080215

• Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy.

  Cancer chemotherapy and pharmacology 20080201

• A coupled drug kinetics-cell cycle model to analyse the response of human cells to intervention by topotecan.

  Computer methods and programs in biomedicine 20080201

• Phase I study of weekly topotecan combined to concurrent external cranial irradiation in adults with glioblastoma multiforme of the brain.

  Oncology reports 20080201

• Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma.

  Investigative ophthalmology & visual science 20080201

• [Chemotherapy for brain tumors in adult patients].

  Der Nervenarzt 20080201

• Small-cell lung cancer, getting smaller but still difficult to treat.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20080201

• A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma.

  Cancer 20080115

• Favorable response of intraommaya topotecan for leptomeningeal metastasis of neuroblastoma after intravenous route failure.

  Pediatric blood & cancer 20080101

• A feasibility study of low-dose, prolonged oral topotecan in patients with advanced ovarian, fallopian tube, or primary peritoneal serous cancer who have attained a complete clinical response following platinum-based chemotherapy.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20080101

• Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors.

  Journal of neuro-oncology 20080101

• Prospective evaluation of weekly topotecan in recurrent platinum-resistant epithelial ovarian cancer.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20080101

• Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma.

  Journal of neuro-oncology 20080101

• A Phase I trial of weekly docetaxel and topotecan for solid tumors.

  Acta oncologica (Stockholm, Sweden) 20080101

• Weekly topotecan for recurrent platinum resistant ovarian cancer.

  Gynecologic oncology 20080101

• Antimetastatic effect of a small-molecule vacuolar H+-ATPase inhibitor in in vitro and in vivo preclinical studies.

  The Journal of pharmacology and experimental therapeutics 20080101

• A phase II study of topotecan and docetaxel in patients with sensitive relapse small cell lung cancer.

  Acta oncologica (Stockholm, Sweden) 20080101

• Prognostic factors in patients treated with taxane-based chemotherapy for recurrent or metastatic endometrial cancer: proposal for a new prognostic model.

  Gynecologic oncology 20080101

• Semi-mechanistic description of the in-vitro antiproliferative effect of different antitumour agents.

  The Journal of pharmacy and pharmacology 20080101

• Topotecan and small interfering RNA suppress survivin expression synergistically in Caki-1 renal cancer cells: Direct suppression of survivin and enhancement of transfection efficiency by topotecan.

  International journal of oncology 20080101

• Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080101

• Preparation, optimization, and characterization of topotecan loaded PEGylated liposomes using factorial design.

  Drug development and industrial pharmacy 20080101

• Binding of topotecan to a nicked DNA oligomer in solution.

  Chemistry (Weinheim an der Bergstrasse, Germany) 20080101

• Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids.

  BMC genomics 20080101

• A phase II, multicenter trial of weekly topotecan in patients with recurrent platinum-sensitive epithelial cancers of the ovary and peritoneum.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20080101

• Multiple myeloma emerging after chemotherapy for non-small-cell lung cancer.

  Medical oncology (Northwood, London, England) 20080101

• Extrapulmonary small cell carcinoma: involvement of the brain without evidence of extracranial malignancy by serial PET/CT scans.

  World journal of surgical oncology 20080101

• Small-cell lung cancer: an unusual therapeutic approach with more than 10-year overall survival. Case report and review of the literature.

  Tumori 20080101

• Intestinal permeability and toxicity of second-line therapeutic agents in ovarian cancer.

  Tumori 20080101

• [Evaluation of second-line chemotherapies most often used in recurrent epithelial ovarian cancer].

  Orvosi hetilap 20071209

• Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP).

  Journal of pharmaceutical sciences 20071201

• Mathematical modeling of topotecan pharmacokinetics and toxicodynamics in mice.

  Journal of pharmacokinetics and pharmacodynamics 20071201

• Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors.

  Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20071201

• Concurrent determination of topotecan and model permeability markers (atenolol, antipyrine, propranolol and furosemide) by reversed phase liquid chromatography: utility in Caco-2 intestinal absorption studies.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20071115

• Population pharmacokinetic analysis of topotecan in pediatric cancer patients.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071115

• TDP1 facilitates chromosomal single-strand break repair in neurons and is neuroprotective in vivo.

  The EMBO journal 20071114

• Spinocerebellar ataxia with axonal neuropathy: consequence of a Tdp1 recessive neomorphic mutation?

  The EMBO journal 20071114

• Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.

  Cancer chemotherapy and pharmacology 20071101

• Determination of topotecan in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography.

  Biomedical chromatography : BMC 20071101

• Flow cytometry analysis of single-strand DNA damage in neuroblastoma cell lines using the F7-26 monoclonal antibody.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20071101

• The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids.

  British journal of pharmacology 20071101

• P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20071101

• Prolonged response to oral gefitinib, cyclophosphamide, and topotecan in heavily pretreated relapsed stage 4 neuroblastoma: a case report.

  Journal of pediatric hematology/oncology 20071101

• Integrated computational strategies for UV/vis spectra of large molecules in solution.

  Chemical Society reviews 20071101

• Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071020

• UVC inhibits HIF-1alpha protein translation by a DNA damage- and topoisomerase I-independent pathway.

  Oncogene 20071018

• The relationship between the down-regulation of DNA-PKcs or Ku70 and the chemosensitization in human cervical carcinoma cell line HeLa.

  Oncology reports 20071001

• Chemotherapy for recurrent cervical cancer.

  Gynecologic oncology 20071001

• The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.

  Cancer research 20071001

• Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia.

  Leukemia & lymphoma 20071001

• Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells.

  Molecular cancer therapeutics 20071001

• Recent advances with topotecan in the treatment of lung cancer.

  The oncologist 20071001

• [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].

  Zhonghua fu chan ke za zhi 20071001

• Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma.

  Journal of cancer research and clinical oncology 20070901

• Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial.

  Journal of cancer research and clinical oncology 20070901

• Involvement of rat and human organic anion transporter 3 in the renal tubular secretion of topotecan [(S)-9-dimethylaminomethyl-10-hydroxy-camptothecin hydrochloride].

  The Journal of pharmacology and experimental therapeutics 20070901

• Differential gene expression in anticancer drug- and TRAIL-mediated apoptosis in renal cell carcinomas.

  Apoptosis : an international journal on programmed cell death 20070901

• A prospective phase II study of induction carboplatin and vinorelbine followed by concomitant topotecan and accelerated radiotherapy (ART) in locally advanced non-small cell lung cancer (NSCLC).

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070901

• Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells.

  Journal of molecular biology 20070824

• Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?

  Pediatric blood & cancer 20070801

• UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium.

  Gynecologic oncology 20070801

• Topotecan vitreous levels after periocular or intravenous delivery in rabbits: an alternative for retinoblastoma chemotherapy.

  Investigative ophthalmology & visual science 20070801

• Torque and dynamics of linking number relaxation in stretched supercoiled DNA.

  Physical review. E, Statistical, nonlinear, and soft matter physics 20070801

• Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070720

• Antitumour drugs impede DNA uncoiling by topoisomerase I.

  Nature 20070712

• A phase I/II trial of topotecan and radiation therapy for brain metastases in patients with solid tumors.

  International journal of radiation oncology, biology, physics 20070701

• Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma.

  Lung cancer (Amsterdam, Netherlands) 20070701

• A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20070701

• Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients.

  Drug metabolism and disposition: the biological fate of chemicals 20070701

• Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070701

• Antiproliferation in human EA.hy926 endothelial cells and inhibition of VEGF expression in PC-3 cells by topotecan.

  Die Pharmazie 20070701

• Effect of pH and human serum albumin on the cytotoxicity of a glucuronide prodrug of 9-aminocamptothecin.

  Cancer chemotherapy and pharmacology 20070601

• Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer.

  Cancer chemotherapy and pharmacology 20070601

• Cholesterol potentiates ABCG2 activity in a heterologous expression system: improved in vitro model to study function of human ABCG2.

  The Journal of pharmacology and experimental therapeutics 20070601

• A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study.

  Gynecologic oncology 20070601

• A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070601

• Topotecan for the treatment of small-cell lung cancer.

  Expert review of anticancer therapy 20070601

• Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070520

• The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2).

  British journal of pharmacology 20070501

• Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children's Cancer Group (CCG) 7943.

  Cancer 20070415

• High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy.

  Pediatric blood & cancer 20070401

• Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer.

  Gynecologic oncology 20070401

• Replication-deficient adenovirus induces host topoisomerase I activity: implications for adenovirus-mediated gene expression.

  Molecular therapy : the journal of the American Society of Gene Therapy 20070401

• Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070401

• [TP53 and RB tumor suppressor pathways collaborate in retinoblastoma genesis].

  Medecine sciences : M/S 20070401

• Phenoxodiol-Topotecan co-administration exhibit significant anti-tumor activity without major adverse side effects.

  Cancer biology & therapy 20070401

• Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer.

  International journal of radiation oncology, biology, physics 20070315

• A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy.

  Gynecologic oncology 20070301

• Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models.

  International journal of cancer 20070301

• Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.

  Leukemia 20070301

• Synergistic effect of survivin-specific small interfering RNA and topotecan in renal cancer cells: topotecan enhances liposome-mediated transfection by increasing cellular uptake.

  International journal of oncology 20070301

• Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.

  Molecular cancer therapeutics 20070301

• Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.

  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20070301

• Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070215

• A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma.

  Gynecologic oncology 20070201

• Effects of topotecan treatment on nasal, buccal, and lingual mucosa in the rabbit: light and transmission electron microscopic evaluation.

  European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 20070201

• Topotecan in the management of cervical cancer.

  Expert opinion on pharmacotherapy 20070201

• Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial.

  Journal of pediatric hematology/oncology 20070201

• New Agents in Clinical Oncology. 24 November 2006, London, UK.

  IDrugs : the investigational drugs journal 20070201

• Amrubicin for the treatment of small cell lung cancer: does effectiveness cross the Pacific?

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070201

• Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts.

  Neuro-oncology 20070101

• The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models.

  Molecular pharmacology 20070101

• Randomised phase II study comparing topotecan/carboplatin administration for 5 versus 3 days in the treatment of extensive-stage small-cell lung cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070101

• Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54(p53wt) and U251(p53mut) glioblastoma cell lines.

  Pharmacological research 20070101

• Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer.

  Expert opinion on drug safety 20070101

• Interferon beta-mediated vessel stabilization improves delivery and efficacy of systemically administered topotecan in a murine neuroblastoma model.

  Journal of pediatric surgery 20070101

• Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients.

  The oncologist 20070101

• Effectiveness of weekly topotecan in patients with recurrent epithelial ovarian cancer.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20070101

• Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20070101

• Topotecan more effective than supportive care.

  The Lancet. Oncology 20070101

• A phase II clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20070101

• Cyclophosphamide 'metronomic' chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer.

  BMC cancer 20070101

• Duration of chemotherapy with topotecan influences survival in recurrent ovarian cancer: a meta-analysis.

  Anticancer research 20070101

• STEALTH liposomal CKD-602, a topoisomerase I inhibitor, improves the therapeutic index in human tumor xenograft models.

  Anticancer research 20070101

• Phase I/II study of IV topotecan in combination with whole brain radiation for the treatment of brain metastases.

  Medical oncology (Northwood, London, England) 20070101

• A novel camptothecin analog with enhanced antitumor activity.

  Anticancer research 20070101

• Topotecan in cervical cancer.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20070101

• Bone metastasis from ovarian cancer.

  Journal of cancer research and therapeutics 20070101

• Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS).

  Klinische Padiatrie 20070101

• Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer.

  BMC cancer 20070101

• Using novobiocin as a specific inhibitor of breast cancer resistant protein to assess the role of transporter in the absorption and disposition of topotecan.

  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20070101

• Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy.

  Oncology 20070101

• ABCG2 expression, function, and promoter methylation in human multiple myeloma.

  Blood 20061201

• Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20061201

• Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells.

  Biological chemistry 20061201

• Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061201

• Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor.

  Cancer research 20061201

• Altered intravenous pharmacokinetics of topotecan in rats with acute renal failure (ARF) induced by uranyl nitrate: do adenosine A1 antagonists (selective/non-selective) normalize the altered topotecan kinetics in ARF?

  Xenobiotica; the fate of foreign compounds in biological systems 20061201

• Cucurbitane triterpenes from the fruiting bodies and cultivated mycelia of Leucopaxillus gentianeus.

  Journal of natural products 20061201

• A review of topoisomerase inhibition in lung cancer.

  Cancer biology & therapy 20061201

• Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.

  Pediatric blood & cancer 20061101

• Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.

  Pediatric blood & cancer 20061101

• BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.

  Cancer chemotherapy and pharmacology 20061101

• Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group.

  Gynecologic oncology 20061101

• Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.

  Gynecologic oncology 20061101

• Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen.

  Gynecologic oncology 20061101

• Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20061101

• Microtransponders, the miniature RFID electronic chips, as platforms for cell growth in cytotoxicity assays.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20061101

• Intrathecal topotecan in adult patients with neoplastic meningitis.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20061101

• Human and murine macrophages mediate activation of MEN 4901/T-0128: a new promising camptothecin analogue-polysaccharide conjugate.

  Anti-cancer drugs 20061101

• Cerebral and parotid metachronous metastases from an ovarian carcinoma.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20061101

• Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20061101

• [Ginsenosides and dexamethasone in managing the liver injury and renal function after transcatheter arterial chemoembolization for hepatic carcinoma patient].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20061101

• Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial.

  Cancer chemotherapy and pharmacology 20061001

• CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan.

  Gynecologic oncology 20061001

• Antitumor activity of nifurtimox observed in a patient with neuroblastoma.

  Journal of pediatric hematology/oncology 20061001

• New drugs for the treatment of metastatic or refractory soft tissue sarcomas in children.

  Future oncology (London, England) 20061001

• Papillary serous carcinoma of peritoneum: presentation of 2 cases.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20061001

• Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer.

  Oncology (Williston Park, N.Y.) 20061001

• Assessment of supra-additive effects of cytotoxic drugs and low dose rate irradiation in an in vitro model for hepatocellular carcinoma.

  Canadian journal of physiology and pharmacology 20061001

• Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060915

• Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.

  Cancer chemotherapy and pharmacology 20060901

• Effect of a novel vacuolar-H+-ATPase inhibitor on cell and tumor response to camptothecins.

  The Journal of pharmacology and experimental therapeutics 20060901

• Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignancies.

  Investigational new drugs 20060901

• Topotecan therapy in patients with relapsed small-cell lung cancer and poor performance status.

  Clinical lung cancer 20060901

• Copper-topotecan complexation mediates drug accumulation into liposomes.

  Journal of controlled release : official journal of the Controlled Release Society 20060810

• Is it time for some new approaches for treating advanced ovarian cancer?

  Journal of the National Cancer Institute 20060802

• Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.

  Journal of the National Cancer Institute 20060802

• Phase-I study of a new schedule based on increasing days of topotecan administration associated with dose individualisation.

  Cancer chemotherapy and pharmacology 20060801

• Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study.

  Gynecologic oncology 20060801

• Activation of ATM and histone H2AX phosphorylation induced by mitoxantrone but not by topotecan is prevented by the antioxidant N-acetyl-L-cysteine.

  Cancer biology & therapy 20060801

• A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20060801

• Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906.

  Leukemia & lymphoma 20060801

• Important differences between topoisomerase-I and -II targeting agents.

  Cancer biology & therapy 20060801

• Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management.

  Danish medical bulletin 20060801

• Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060720

• Prospective trial on topotecan salvage therapy in primary CNS lymphoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060701

• Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.

  Neuro-oncology 20060701

• Oral second-line chemotherapy for advanced non-small-cell lung cancer: the bottom line.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060620

• Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060620

• Second-line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a phase II study.

  Cancer chemotherapy and pharmacology 20060601

• A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer.

  Cancer chemotherapy and pharmacology 20060601

• Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer.

  The European respiratory journal 20060601

• Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice.

  European journal of clinical investigation 20060601

• Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?

  Expert opinion on pharmacotherapy 20060601

• American Association for Cancer Research--97th annual meeting.

  IDrugs : the investigational drugs journal 20060601

• Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer.

  American journal of clinical oncology 20060601

• A novel stealth liposomal topotecan with amlodipine: apoptotic effect is associated with deletion of intracellular Ca2+ by amlodipine thus leading to an enhanced antitumor activity in leukemia.

  Journal of controlled release : official journal of the Controlled Release Society 20060515

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Reponses to topoisomerase-I inhibitors in extensive small-cell lung cancer: chance or chromosomes?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060501

• Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060501

• Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo.

  Cancer research 20060501

• Topotecan continuous infusion: CA-125 responses including patients pretreated with other schedules of topotecan.

  The oncologist 20060501

• A phase II study of gemcitabine and immunotherapy in renal cancer: preliminary results and review of the literature.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060501

• Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children.

  Cancer chemotherapy and pharmacology 20060401

• Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.

  Gynecologic oncology 20060401

• Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells.

  Blood 20060401

• Concurrent chemoradiotherapy and adjuvant chemotherapy with Topotecan for patients with glioblastoma multiforme.

  Journal of neuro-oncology 20060401

• A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group.

  Journal of neuro-oncology 20060401

• Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma.

  Neuro-oncology 20060401

• Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol.

  Bone marrow transplantation 20060401

• Chemotherapy in the management of cervical carcinoma.

  Clinical advances in hematology & oncology : H&O 20060401

• A study of variable hydration states in topotecan hydrochloride.

  Journal of pharmaceutical and biomedical analysis 20060318

• Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate carcinoma cells.

  Biochemical pharmacology 20060314

• Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study.

  Gynecologic oncology 20060301

• Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes.

  Leukemia & lymphoma 20060301

• Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma.

  Leukemia & lymphoma 20060301

• Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.

  Cancer 20060301

• Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

  Health technology assessment (Winchester, England) 20060301

• [Inhibition effect of topotecan on human myelodysplastic syndrome cells in vitro and in vivo].

  Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 20060301

• Topotecan and paclitaxel in previously treated patients with relapsed small cell lung cancer: phase II trial of the North Central Cancer Treatment Group.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20060301

• Comparison of efficacy and toxicity profile between intraperitoneal and intravenous topotecan in human ovarian cancer xenografts.

  Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 20060218

• Effects of drug combinations on smooth muscle cell proliferation: an isobolographic analysis.

  European journal of pharmacology 20060217

• Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study.

  Gynecologic oncology 20060201

• Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1.

  Molecular pharmacology 20060201

• Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060201

• Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system.

  Bone marrow transplantation 20060201

• ATM activation and histone H2AX phosphorylation as indicators of DNA damage by DNA topoisomerase I inhibitor topotecan and during apoptosis.

  Cell proliferation 20060201

• Altered phosphorylation of topoisomerase I following overexpression in an ovarian cancer cell line.

  Biochemistry and cell biology = Biochimie et biologie cellulaire 20060201

• A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.

  Molecular cancer therapeutics 20060201

• [Is small cell lung cancer an orphan disease?].

  Revue de pneumologie clinique 20060201

• [From ASCO and WCLC 2005 to clinical practice: 'conventional' treatments].

  Revue de pneumologie clinique 20060201

• Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors.

  Cancer chemotherapy and pharmacology 20060101

• Combination of topotecan and cisplatin in relapsed patients with small cell lung cancer: a phase II study of the hellenic cooperative oncology group (HeCOG).

  Cancer chemotherapy and pharmacology 20060101

• A phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: a Gynecologic Oncology Group study.

  Gynecologic oncology 20060101

• Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study.

  Cancer chemotherapy and pharmacology 20060101

• Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy.

  Gynecologic oncology 20060101

• Topotecan can compensate for protracted radiation treatment time effects in high grade glioma xenografts.

  Journal of neuro-oncology 20060101

• Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060101

• Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.

  BMC cancer 20060101

• Phase I/II study of tandem cycles of high-dose chemotherapy followed by autologous hematopoietic stem cell support in women with advanced ovarian cancer.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101

• Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101

• Ethnicity is a factor to be considered before dose planning in ovarian cancer patients to be treated with topotecan.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101

• Topotecan is a substrate for multidrug resistance associated protein 4.

  Current drug metabolism 20060101

• Early patterns of verbal memory impairment in children treated for medulloblastoma.

  Neuropsychology 20060101

• Topotecan and liposomal doxorubicin in recurrent ovarian cancer: is sequence important?

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101

• Is there a role for neoadjuvant chemotherapy in the treatment of stage IV serous endometrial carcinoma?

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101

• Recurrent ovarian cancer metastatic to the sternum, costae, and thoracic wall after prolonged treatment with platinum-based chemotherapy: a case report and review of the literature.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101

• Topotecan in the treatment of brain metastases. A phase II study of GOIM (Gruppo Oncologico dell'Italia Meridionale).

  Anticancer research 20060101

• New agents for intrathecal administration.

  Cancer investigation 20060101

• Topotecan, Ara-C, cisplatin and prednisolone (Toposhap) for patients with refractory and relapsing lymphomas: Results of a phase II trial.

  Acta haematologica 20060101

• A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.

  Clinical drug investigation 20060101

• Topotecan as a second-line therapy in patients with ovarian and primary peritoneal cancer: initial response and long-term follow-up.

  European journal of gynaecological oncology 20060101

• Combinational effect of topotecan and octreotide on murine leukemia cells in vivo and in vitro.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20060101

• Drug approved for late-stage cervical cancer.

  FDA consumer 20060101

• Esters and amides of 2,3-dimethoxy-8,9-methylenedioxy-benzo[i]phenanthridine-12-carboxylic acid: potent cytotoxic and topoisomerase I-targeting agents.

  Bioorganic & medicinal chemistry 20051215

• Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: results of a French Society of Paediatric Oncology Phase II Study.

  Cancer 20051215

• A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma.

  Gynecologic oncology 20051201

• Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial.

  Oncology reports 20051201

• The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051201

• Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.

  Haematologica 20051201

• Phase I study of docetaxel and topotecan in patients with advanced malignancies.

  Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20051201

• New hints on the Ph-driven tautomeric equilibria of the topotecan anticancer drug in aqueous solutions from an integrated spectroscopic and quantum-mechanical approach.

  Journal of the American Chemical Society 20051109

• Augmenting tumor sensitivity to topotecan by transient hypoxia.

  Cancer chemotherapy and pharmacology 20051101

• Non-enrolment of ovarian cancer patients in clinical trials: reasons and background.

  Annals of oncology : official journal of the European Society for Medical Oncology 20051101

• Assessment of ATM phosphorylation on Ser-1981 induced by DNA topoisomerase I and II inhibitors in relation to Ser-139-histone H2AX phosphorylation, cell cycle phase, and apoptosis.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20051101

• [131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051101

• Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group.

  Clinical lung cancer 20051101

• Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer.

  Clinical lung cancer 20051101

• [131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma.

  Cancer letters 20051018

• The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan.

  Biochemical pharmacology 20051015

• Topotecan combination chemotherapy in two new rodent models of retinoblastoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051015

• Phase II study of topotecan and cyclophosphamide in patients with relapsed and refractory multiple myeloma.

  Leukemia research 20051001

• Hypoxia inducible factor-1: a novel target for cancer therapy.

  Anti-cancer drugs 20051001

• Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival.

  Cancer research 20051001

• Topotecan in platinum-resistant epithelial ovarian cancer.

  Chemotherapy 20051001

• Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis.

  The oncologist 20051001

• Topotecan as second-line therapy for ovarian cancer: dosage versus toxicity.

  The oncologist 20051001

• Topotecan: weighing in when there are many options.

  The oncologist 20051001

• Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial.

  The oncologist 20051001

• In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan.

  The Journal of pharmacy and pharmacology 20051001

• Single-agent topotecan as first-line chemotherapy in women with metastatic breast cancer: final results of eastern cooperative oncology group trial E8193.

  Clinical breast cancer 20051001

• Fluorescence detection combined with either HPLC or HPTLC for pharmaceutical quality control in a hospital chemotherapy production unit: application to camptothecin derivatives.

  Journal of pharmaceutical and biomedical analysis 20050915

• One- and two-stage designs for stratified phase II clinical trials.

  Statistics in medicine 20050915

• Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050915

• Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma.

  Gynecologic oncology 20050901

• Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma.

  Journal of cancer research and clinical oncology 20050901

• Modern management of recurrent ovarian carcinoma. A systematic approach to a chronic disease.

  Oncology (Williston Park, N.Y.) 20050901

• Macromolecular and nanotechnological modification of camptothecin and its analogs to improve the efficacy.

  Current drug discovery technologies 20050901

• Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050815

• New drugs target hypoxia response in tumors.

  Journal of the National Cancer Institute 20050803

• Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.

  Cancer chemotherapy and pharmacology 20050801

• Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.

  Drug metabolism and disposition: the biological fate of chemicals 20050801

• Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study.

  Gynecologic oncology 20050801

• Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma.

  Gynecologic oncology 20050801

• A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20050801

• Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.

  Cancer research 20050801

• Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050720

• Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050720

• A noninvasive approach for assessing tumor hypoxia in xenografts: developing a urinary marker for hypoxia.

  Cancer research 20050715

• Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer.

  British journal of cancer 20050711

• A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours.

  British journal of cancer 20050711

• Chemotherapy dosing in the setting of liver dysfunction.

  Oncology (Williston Park, N.Y.) 20050701

• Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050620

• Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen.

  Lung cancer (Amsterdam, Netherlands) 20050601

• Randomized phase II study comparing topotecan/cisplatin administration for 5 days versus 3 days in the treatment of extensive stage small cell lung cancer (SCLC).

  Lung cancer (Amsterdam, Netherlands) 20050601

• Effect of ABCG2 genotype on the oral bioavailability of topotecan.

  Cancer biology & therapy 20050601

• DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation.

  Molecular and cellular biology 20050601

• Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells.

  Cancer research 20050601

• Management of leptomeningeal malignancy.

  Expert opinion on pharmacotherapy 20050601

• High dose chemotherapy and transplantation of hematopoietic progenitors from murine D3 embryonic stem cells.

  Journal of chemotherapy (Florence, Italy) 20050601

• The effect of quercetin on topotecan cytotoxicity in MCF-7 and MDA-MB 231 human breast cancer cells.

  The Journal of surgical research 20050501

• Chronomodulation of topotecan or X-radiation treatment increases treatment efficacy without enhancing acute toxicity.

  International journal of radiation oncology, biology, physics 20050501

• Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.

  Chemotherapy 20050501

• Cell cycle effects of topotecan alone and in combination with irradiation.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20050501

• In vitro and in vivo studies of different liposomes containing topotecan.

  Archives of pharmacal research 20050501

• Simple and sensitive high performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of topotecan in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050425

• Serum cystatin C is a better marker of topotecan clearance than serum creatinine.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050415

• Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study.

  Cancer 20050401

• CA125 Nadir values as a prognostic factor in epithelial ovarian cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050401

• Open-label simultaneous radio-chemotherapy of glioblastoma multiforme with topotecan in adults.

  Clinical neurology and neurosurgery 20050401

• [Effect of bone marrow stromal cells on the apoptotic sensitivity of HL-60 and HL-60/VCR cells].

  Zhongguo shi yan xue ye xue za zhi 20050401

• Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.

  Cancer biotherapy & radiopharmaceuticals 20050401

• Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.

  Drug metabolism and disposition: the biological fate of chemicals 20050301

• A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer.

  European journal of cancer (Oxford, England : 1990) 20050301

• Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.

  British journal of cancer 20050227

• High-performance liquid chromatographic assay for the determination of total and free topotecan in the presence and absence of anti-topotecan antibodies in mouse plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050225

• In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy.

  International journal of cancer 20050220

• Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.

  Cancer research 20050215

• MEN4901/T-0128, a new camptothecin derivative-carboxymethyldextran conjugate, has potent antitumor activities in a panel of human tumor xenografts in nude mice.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050215

• Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease.

  Gynecologic oncology 20050201

• A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma.

  Journal of neuro-oncology 20050201

• Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models.

  Neoplasia (New York, N.Y.) 20050201

• Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2.

  Cancer research 20050115

• Advanced microscopy solutions for monitoring the kinetics and dynamics of drug-DNA targeting in living cells.

  Advanced drug delivery reviews 20050102

• Panniculitis induced by a chemotherapy regimen consisting of topotecan and cyclophosphamide.

  Pediatric blood & cancer 20050101

• Novel assay utilizing fluorochrome-tagged physostigmine (Ph-F) to in situ detect active acetylcholinesterase (AChE) induced during apoptosis.

  Cell cycle (Georgetown, Tex.) 20050101

• Efficacy of topotecan treatment on antioxidant enzymes and TBA-RS levels in submandibular glands of rabbits: an experimental study.

  Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 20050101

• Phase I/II trial of simultaneous whole-brain irradiation and dose-escalating topotecan for brain metastases.

  Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20050101

• Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck.

  Expert opinion on pharmacotherapy 20050101

• Toxicity of the topoisomerase I inhibitors.

  Expert opinion on drug safety 20050101

• In vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant glioma.

  Journal of neuro-oncology 20050101

• High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors.

  Journal of neuro-oncology 20050101

• The effects of topotecan on lipid peroxidation and antioxidant enzyme levels in rabbit liver tissue.

  Redox report : communications in free radical research 20050101

• Topotecan in heavily pretreated patients with recurrent ovarian, peritoneal, and fallopian tube carcinoma.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20050101

• Cancer cell adaptation to chemotherapy.

  BMC cancer 20050101

• Recent developments in the clinical activity of topoisomerase-1 inhibitors.

  Cancer chemotherapy and biological response modifiers 20050101

• p53 Gene status and response to topotecan-containing chemotherapy in advanced ovarian carcinoma.

  Oncology 20050101

• Effect of chemotherapy on the mutation frequency of ovarian cancer cells at the HPRT locus.

  Anticancer research 20050101

• Phase I trial of an all-oral combination chemotherapy regimen: topotecan and capecitabine in solid tumor patients.

  The Journal of oncology management : the official journal of the American College of Oncology Administrators 20050101

• Efficacy and tolerability of lower-dose topotecan in recurrent ovarian cancer: a retrospective case review.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20050101

• A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.

  Cancer investigation 20050101

• The effect of Topotecan on oxidative stress in MCF-7 human breast cancer cell line.

  Acta biochimica Polonica 20050101

• Breast cancer resistance protein-mediated topotecan resistance in ovarian cancer cells.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20050101

• Randomized single-agents trials in recurrent epithelial ovarian cancer.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20050101

• Phase I clinical trial of topotecan and pegylated liposomal doxorubicin.

  Cancer investigation 20050101

• The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.

  Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 20050101

• Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin.

  The Journal of biological chemistry 20041224

• HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2',5'-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand.

  Cancer research 20041215

• Heterogeneous cell response to topotecan in a CFSE-based proliferation test.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20041201

• Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer.

  Gynecologic oncology 20041201

• Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer.

  Gynecologic oncology 20041201

• Pharmacokinetic model-predicted anticancer drug concentrations in human tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041201

• In regard to Bogart et al.: 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage non-small-cell lung cancer: Analysis of cancer and leukemia group B study 39808 (Int J Radiat Oncol Biol Phys 2004;59:460-468).

  International journal of radiation oncology, biology, physics 20041201

• Mechanism-based models for topotecan-induced neutropenia.

  Clinical pharmacology and therapeutics 20041201

• The use of topotecan for relapsed ovarian cancer in accordance with the National Institute for Clinical Excellence Guidance 2001: the Nottingham experience.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20041201

• Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference.

  Molecular cancer therapeutics 20041201

• Emerging therapeutic and supportive care approaches for the myelodisplastic syndromes.

  Reviews in clinical and experimental hematology 20041201

• Recurrent ovarian cancer: how important is it to treat to disease progression?

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041115

• Review of the use of topotecan in ovarian carcinoma.

  Expert opinion on pharmacotherapy 20041101

• Topotecan induced nail pigmentation.

  The Journal of dermatology 20041101

• [Effect of palliative chemotherapy with topoisomerase inhibitor on the quality of life and survival of patients with advanced colorectal carcinoma].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20041101

• Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20041015

• A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041015

• Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.

  Gynecologic oncology 20041001

• Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers.

  Gynecologic oncology 20041001

• Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature.

  Gynecologic oncology 20041001

• Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts.

  Cancer research 20041001

• Implications of p53 in growth arrest and apoptosis on combined treatment of human Mammary epithelial cells with topotecan and UCN-01.

  Journal of experimental therapeutics & oncology 20041001

• Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040915

• Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study.

  Cancer chemotherapy and pharmacology 20040901

• Microbore HPLC method with online microdialysis for measurement of topotecan lactone and carboxylate in murine CSF.

  Journal of pharmaceutical sciences 20040901

• Topotecan versus paclitaxel in second-line therapy: a lost opportunity for quality-of-life evaluation?

  Annals of oncology : official journal of the European Society for Medical Oncology 20040901

• Topotecan disposition in an anephric child.

  Journal of pediatric hematology/oncology 20040901

• Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow cytometric high-content screening.

  Journal of immunological methods 20040901

• Gefitinib reverses breast cancer resistance protein-mediated drug resistance.

  Molecular cancer therapeutics 20040901

• Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040815

• Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.

  Cancer research 20040815

• Synthesis and cytotoxicity of water soluble quaternary salt derivatives of camptothecin.

  Bioorganic & medicinal chemistry letters 20040802

• Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancer.

  Cancer chemotherapy and pharmacology 20040801

• Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum?

  Gynecologic oncology 20040801

• Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.

  Gynecologic oncology 20040801

• [Synthesis and antitumor activity of 20-O-linked camptothecin ester derivatives].

  Yao xue xue bao = Acta pharmaceutica Sinica 20040801

• Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo.

  Carcinogenesis 20040701

• The telomeric region is excluded from nucleosomal fragmentation during apoptosis, but the bulk nuclear chromatin is randomly degraded.

  Cell death and differentiation 20040701

• Combined topoisomerase I inhibition for the treatment of metastatic colon cancer.

  Anti-cancer drugs 20040701

• Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040701

• The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.

  Gynecologic oncology 20040701

• Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.

  Gynecologic oncology 20040701

• [A case of brain metastasis of small cell lung cancer improved with nogitecan hydrochloride (topotecan) after prophylactic irradiation].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040701

• Topotecan-induced bronchiolitis.

  Southern medical journal 20040701

• A non-parametric approach to the design and analysis of two-dimensional dose-finding trials.

  Statistics in medicine 20040630

• A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors.

  Cancer 20040615

• Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance.

  Cancer research 20040615

• Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.

  British journal of cancer 20040614

• A mathematical model for the in vitro kinetics of the anti-cancer agent topotecan.

  Mathematical biosciences 20040601

• A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML.

  Leukemia research 20040601

• 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808.

  International journal of radiation oncology, biology, physics 20040601

• Topotecan in patients with advanced neuroendocrine tumors: a phase II study with significant hematologic toxicity.

  American journal of clinical oncology 20040601

• Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials.

  Gynecologic oncology 20040601

• Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies.

  Gynecologic oncology 20040601

• Topoisomerase I inhibitors in the combined-modality therapy of lung cancer.

  Oncology (Williston Park, N.Y.) 20040601

• Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan.

  Neurology 20040525

• An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes.

  Journal of controlled release : official journal of the Controlled Release Society 20040518

• Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors.

  Cancer 20040515

• Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer.

  Gynecologic oncology 20040501

• Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts.

  European journal of cancer (Oxford, England : 1990) 20040501

• Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age.

  Acta paediatrica (Oslo, Norway : 1992). Supplement 20040501

• [Homocamptothecins--novel promising anticancer drugs as inhibitors of topoisomerase I].

  Yao xue xue bao = Acta pharmaceutica Sinica 20040501

• Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040415

• A window on reality?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040415

• Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology.

  Cancer 20040415

• Overexpression of a dominant-negative mutant Ubc9 is associated with increased sensitivity to anticancer drugs.

  Cancer research 20040415

• Cytostatic and cytotoxic effects of topotecan decoded by a novel mathematical simulation approach.

  Cancer research 20040415

• A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies.

  Lung cancer (Amsterdam, Netherlands) 20040401

• Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer.

  Gynecologic oncology 20040401

• A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer.

  Gynecologic oncology 20040401

• Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20040401

• Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.

  Cancer research 20040401

• A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.

  Leukemia research 20040401

• [Structure-activity relationship analysis].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040401

• Hematological response of topotecan in tumor-bearing rats: modeling of the time course of different cellular populations.

  Pharmaceutical research 20040401

• Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia.

  Leukemia & lymphoma 20040401

• High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma.

  Leukemia & lymphoma 20040401

• Subcellular localization of the camptothecin analogues, topotecan and gimatecan.

  Biochemical pharmacology 20040315

• Quality of life evaluations in patients with ovarian cancer during chemotherapy treatment.

  Gynecologic oncology 20040301

• Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040301

• Evolving role of topotecan in treating small-cell lung cancer.

  Clinical lung cancer 20040301

• [The mechanism of topotecan resistance in ovarian cancer cell line].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20040301

• Activity of topotecan in retinoblastoma.

  Ophthalmic genetics 20040301

• A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer.

  British journal of cancer 20040223

• 11H-Isoquino[4,3-c]cinnolin-12-ones; novel anticancer agents with potent topoisomerase I-targeting activity and cytotoxicity.

  Bioorganic & medicinal chemistry 20040215

• Pheophorbide a is a specific probe for ABCG2 function and inhibition.

  Cancer research 20040215

• Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications.

  Cancer research 20040215

• Targeting topoisomerase I to inhibit hypoxia inducible factor 1.

  Cell cycle (Georgetown, Tex.) 20040201

• Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040201

• Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma.

  Gynecologic oncology 20040201

• Synergistic cytotoxicity of pyrazoloacridine with doxorubicin, etoposide, and topotecan in drug-resistant tumor cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040201

• Recurrent ovarian cancer.

  Onkologie 20040201

• Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum.

  Onkologie 20040201

• Factors affecting pharmacokinetic variability of oral topotecan: a population analysis.

  British journal of cancer 20040126

• Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?

  British journal of cancer 20040126

• Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein.

  Leukemia 20040101

• A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.

  Cancer chemotherapy and pharmacology 20040101

• Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.

  International journal of cancer 20040101

• Phase II study of low-dose topotecan in myelodysplastic syndromes: a Hoosier Oncology Group (HOG) study.

  Leukemia research 20040101

• Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20040101

• Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries.

  The American journal of medicine 20040101

• A phase II study of topotecan and cyclophosphamide with G-CSF in patients with advanced small cell lung cancer.

  Cancer biology & therapy 20040101

• Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040101

• Topotecan in small cell lung cancer: first or second line?

  Cancer biology & therapy 20040101

• Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors.

  Pediatric blood & cancer 20040101

• Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity.

  The oncologist 20040101

• The role of topotecan in the treatment of brain metastases.

  The oncologist 20040101

• Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis.

  Molecular cancer research : MCR 20040101

• Topotecan in the treatment of relapsed small cell lung cancer patients with poor performance status.

  The oncologist 20040101

• High-dose chemotherapy with autologous stem cell rescue as first line of treatment in young children with medulloblastoma and supratentorial primitive neuroectodermal tumors.

  Journal of neuro-oncology 20040101

• Topotecan as a continuous infusion over 14 days in recurrent ovarian cancer patients.

  Anticancer research 20040101

• Inhibitory effect of genistein and daidzein on ovarian cancer cell growth.

  Anticancer research 20040101

• Weekly topotecan in a heavily pretreated patient with peritoneal papillary serous adenocarcinoma.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20040101

• Topotecan-induced alterations in the amount and stability of human DNA topoisomerase I in solid tumor cell lines.

  Anticancer research 20040101

• Effect of association of temozolomide with other chemotherapic agents on cell growth inhibition in glioma cell lines.

  Oncology research 20040101

• Effective knock down of very high ABCG2 expression by a hammerhead ribozyme.

  Anticancer research 20040101

• Topotecan, Ara-C, cisplatin and prednisolone (TOPOSHAP) for patients with refractory and relapsing lymphomas: results of a phase I trial.

  Acta haematologica 20040101

• Phase I trial of topotecan in combination with gemcitabine in refractory solid tumor patients.

  Cancer investigation 20040101

• Ovarian cancer: review of the National Institute for Clinical Excellence (NICE) guidance recommendations.

  Cancer investigation 20040101

• Foreword--new directions for topotecan in lung cancer treatment.

  The oncologist 20040101

• Topotecan in the treatment of recurrent small cell lung cancer: an update.

  The oncologist 20040101

• Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life.

  The oncologist 20040101

• Emerging role of weekly topotecan in recurrent small cell lung cancer.

  The oncologist 20040101

• Topotecan in the first-line treatment of small cell lung cancer.

  The oncologist 20040101

• Update on the role of topotecan in the treatment of non-small cell lung cancer.

  The oncologist 20040101

• [Status report on the chemotherapy of ovarian cancer at special cancer centers in Hungary (2002-2003)].

  Magyar onkologia 20040101

• A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma.

  Cancer 20031201

• [Antisense oligonucleotide reverses topotecan-resistant ovarian cancer cells].

  Ai zheng = Aizheng = Chinese journal of cancer 20031201

• [Chemosensitivity testing of topotecan as second-line agent in chemotherapy of ovarian cancer].

  Ai zheng = Aizheng = Chinese journal of cancer 20031201

• Treatment advances in ovarian cancer.

  Cancer nursing 20031201

• Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics.

  British journal of cancer 20031103

• A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma.

  Investigational new drugs 20031101

• An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma.

  Investigational new drugs 20031101

• A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies.

  Gynecologic oncology 20031101

• Phase I study of topotecan in combination with concurrent radiotherapy in adults with glioblastoma.

  Journal of neuro-oncology 20031101

• [Topotecan-based combined chemotherapy for refractory or relapsed hematologic malignancies].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20031101

• [Economic assessment of Caelyx versus topotecan in advanced ovarian cancer].

  Bulletin du cancer 20031101

• Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study.

  Cancer 20031015

• Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer.

  Cancer chemotherapy and pharmacology 20031001

• Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20031001

• A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia.

  Leukemia 20031001

• Apoptotic pathways of epothilone BMS 310705.

  Gynecologic oncology 20031001

• Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain.

  British journal of cancer 20030915

• Phase I study of oral topotecan in hematological malignancies.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030915

• The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis.

  Cancer chemotherapy and pharmacology 20030901

• Interactions of fluorochrome-labeled caspase inhibitors with apoptotic cells: a caution in data interpretation.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20030901

• Clinical experience with topotecan in relapsed ovarian cancer.

  Gynecologic oncology 20030901

• First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer.

  Gynecologic oncology 20030901

• The role of topotecan in the treatment of advanced cervical cancer.

  Gynecologic oncology 20030901

• Treatment options for endometrial cancer: experience with topotecan.

  Gynecologic oncology 20030901

• Weekly topotecan in the management of ovarian cancer.

  Gynecologic oncology 20030901

• Optimal sequencing in the treatment of recurrent ovarian cancer.

  Gynecologic oncology 20030901

• Workshop: options for therapy in ovarian cancer.

  Gynecologic oncology 20030901

• [Current status of camptothecin derivatives as natural antitumor agents].

  Yao xue xue bao = Acta pharmaceutica Sinica 20030901

• [Topotecan for pediatric patients with resistant and recurrent solid tumors].

  Anales de pediatria (Barcelona, Spain : 2003) 20030801

• Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: results of a multicenter phase III trial in patients with advanced gynecologic malignancies.

  Gynecologic oncology 20030801

• Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis.

  Journal of pediatric hematology/oncology 20030801

• Expression and functional analyses of breast cancer resistance protein in lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030801

• CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030801

• Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5.

  Gynecologic oncology 20030801

• Determination of chemotherapeutic activity in vivo by luminescent imaging of luciferase-transfected human tumors.

  Anti-cancer drugs 20030801

• The role of topotecan in treating small cell lung cancer: second-line treatment.

  Lung cancer (Amsterdam, Netherlands) 20030801

• Topotecan as first-line therapy for small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20030801

• Single-agent chemotherapy for non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20030801

• Combination chemotherapy with topotecan for non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20030801

• Weekly topotecan in the management of lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20030801

• Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines.

  European journal of pharmacology 20030725

• New designs for phase 2 clinical trials.

  Blood 20030715

• Survival-signaling pathway as a promising target for cancer chemotherapy.

  Cancer chemotherapy and pharmacology 20030701

• Influence of the cisplatin hydration schedule on topotecan pharmacokinetics.

  European journal of cancer (Oxford, England : 1990) 20030701

• Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030701

• Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030701

• Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy.

  Journal of neurovirology 20030601

• Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030601

• Treatment of relapsed small-cell lung cancer--a focus on the evolving role of topotecan.

  Lung cancer (Amsterdam, Netherlands) 20030601

• Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study.

  Cancer research 20030601

• Second-line chemotherapy for ovarian cancer.

  The Lancet. Oncology 20030601

• A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030601

• Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.

  American journal of clinical oncology 20030601

• A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum.

  The journal of obstetrics and gynaecology research 20030601

• Cost-minimization analysis of pegylated liposomal doxorubicin versus topotecan for the treatment of ovarian cancer in Italy.

  Clinical therapeutics 20030601

• Phase II study to topotecan and cisplatin in advanced hepatocellular carcinoma.

  The Korean journal of internal medicine 20030601

• The egr-1 gene is induced by DNA-damaging agents and non-genotoxic drugs in both normal and neoplastic human cells.

  Life sciences 20030516

• Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.

  Cancer 20030515

• Developmental chemotherapy and management of recurrent ovarian cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030515

• Genotoxicity of two anticancer drugs, gemcitabine and topotecan, in mouse bone marrow in vivo.

  Mutation research 20030509

• The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells.

  International journal of oncology 20030501

• Toxicity patterns of cytotoxic drugs.

  Investigational new drugs 20030501

• ZD9331 in combination with topotecan: phase I and II experience.

  Anti-cancer drugs 20030501

• Tracking the cell cycle origins for escape from topotecan action by breast cancer cells.

  British journal of cancer 20030422

• Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models.

  Biochemical pharmacology 20030415

• Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation.

  Journal of pediatric hematology/oncology 20030401

• [Drug-resistant proteins in breast cancer: recent progress in multidrug resistance].

  Ai zheng = Aizheng = Chinese journal of cancer 20030401

• Phase I trial of carboplatin and paclitaxel with escalating doses of oral topotecan in patients with solid tumors.

  American journal of clinical oncology 20030401

• Inhibition of focal adhesion kinase by antisense oligonucleotides enhances the sensitivity of breast cancer cells to camptothecins.

  Biocell : official journal of the Sociedades Latinoamericanas de Microscopia Electronica ... et. al 20030401

• Population pharmacokinetics/pharmacodynamics relationships of an anticancer drug.

  Statistics in medicine 20030330

• Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030315

• A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.

  Cancer 20030301

• Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis.

  Anti-cancer drugs 20030301

• [Second-line Hycamtin in the treatment of lung cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20030301

• [A symphony for the camptothecins].

  Bulletin du cancer 20030301

• Determination of plasma topotecan and its metabolite N-desmethyl topotecan as both lactone and total form by reversed-phase liquid chromatography with fluorescence detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030205

• A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030201

• A phase II multicenter study of combined topotecan and gemcitabine as first line chemotherapy for advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20030201

• Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer.

  Gynecologic oncology 20030201

• Chemotherapy for small cell lung cancer.

  Seminars in oncology 20030201

• Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors.

  Journal of medicinal chemistry 20030116

• Commentary: topoisomerases as targets in acute leukemia: I, II, I plus II or none?

  Leukemia research 20030101

• A phase I and pharmacodynamic study of sequential topotecan and etoposide in patients with relapsed or refractory acute myelogenous and lymphoblastic leukemia.

  Leukemia research 20030101

• Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study.

  Lung cancer (Amsterdam, Netherlands) 20030101

• Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030101

• Boosting bioavailability to topotecan: what do we gain?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030101

• Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists.

  Molecular cancer therapeutics 20030101

• European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030101

• The MTS assay as an indicator of chemosensitivity/resistance in malignant gynaecological tumours.

  Cancer detection and prevention 20030101

• Phase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer.

  The oncologist 20030101

• A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: first report of the Children's Cancer Group-0952.

  Neuro-oncology 20030101

• [Preclinical studies of concomitant chemoradiation].

  Medicina (Kaunas, Lithuania) 20030101

• Current therapies in ovarian cancer.

  Cancer investigation 20030101

• The use of continuous infusion topotecan in persistent and recurrent ovarian cancer.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20030101

• A pilot study of topotecan in the treatment of serous carcinoma of the uterus.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20030101

• Modeling plasma and saliva topotecan concentration time course using a population approach.

  Oncology research 20030101

• High-dose daunorubicin as liposomal compound (Daunoxome) in elderly patients with acute lymphoblastic leukemia.

  The hematology journal : the official journal of the European Haematology Association 20030101

• p53 status and its in vitro relationship to radiosensitivity and chemosensitivity in lung cancer.

  Anticancer research 20030101

• Prolonged stabilization of platinum/paclitaxel-refractory ovarian cancer with topotecan: a case report and review of the literature.

  Clinical and experimental obstetrics & gynecology 20030101

• Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone.

  Anticancer research 20030101

• DNA damage induced by DNA topoisomerase I- and topoisomerase II-inhibitors detected by histone H2AX phosphorylation in relation to the cell cycle phase and apoptosis.

  Cell cycle (Georgetown, Tex.) 20030101

• Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic non-small cell lung cancer.

  Cancer investigation 20030101

• Interaction of clinically important human DNA topoisomerase I poison, topotecan, with double-stranded DNA.

  Biopolymers 20030101

• Clinical studies of camptothecin and derivatives.

  The Alkaloids. Chemistry and biology 20030101

• Improving first-line therapy of advanced ovarian cancer - the AGO Ovarian Cancer Study Group perspective.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20030101

• [Interaction of topotecan-a DNA topoisomerase I inhibitor-with dual-stranded polydeoxyribonucleotides. V. Topotecan is able to cause single- and double-strand breaks in ring superhelical DNA in the absence of enzyme].

  Molekuliarnaia biologiia 20030101

• Low levels of ABCG2 expression in adult AML blast samples.

  Blood 20021215

• Action models for the antitumor drug camptothecin: formation of alkali-labile complex with DNA and inhibition of human DNA topoisomerase I.

  Journal of biomolecular structure & dynamics 20021201

• Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia.

  Cancer chemotherapy and pharmacology 20021201

• A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study.

  Gynecologic oncology 20021201

• Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20021201

• Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa.

  Bone marrow transplantation 20021201

• Prolonged infusional topotecan and accelerated hyperfractionated 3d-conformal radiation in patients with newly diagnosed glioblastoma--a phase I study.

  Journal of neuro-oncology 20021201

• [Preliminary study of apoptosis of human hepatocarcinoma cell line HepG2 induced by topotecan].

  Ai zheng = Aizheng = Chinese journal of cancer 20021201

• ZD0473 combined with other chemotherapeutic agents for the treatment of solid malignancies.

  European journal of cancer (Oxford, England : 1990) 20021201

• The mechanism of topoisomerase I poisoning by a camptothecin analog.

  Proceedings of the National Academy of Sciences of the United States of America 20021126

• Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure.

  Journal of medicinal chemistry 20021107

• A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20021101

• Unexpected pleural effusions in 3 pediatric patients treated with STI-571.

  Journal of pediatric hematology/oncology 20021101

• A phase I study of weekly topotecan and Paclitaxel in previously treated epithelial ovarian carcinoma patients.

  Gynecologic oncology 20021101

• [Own experiences in salvage chemotherapy of ovarian cancer--a preliminary report].

  Ginekologia polska 20021101

• Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.

  Cancer 20021015

• A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.

  Cancer 20021001

• Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study.

  Lung cancer (Amsterdam, Netherlands) 20021001

• A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK.

  Annals of oncology : official journal of the European Society for Medical Oncology 20021001

• Tumor lysis syndrome in extensive-stage small-cell lung cancer.

  American journal of clinical oncology 20021001

• Detection of topoisomerase inhibitor-induced DNA strand breaks and apoptosis by the alkaline comet assay.

  Mutation research 20020926

• A Phase II trial of topotecan and gemcitabine in patients with previously treated, advanced nonsmall cell lung carcinoma.

  Cancer 20020915

• Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation. a multicentre phase II study.

  European journal of cancer (Oxford, England : 1990) 20020901

• Development of a real-time in vivo transcription assay: application reveals pregnane X receptor-mediated induction of CYP3A4 by cancer chemotherapeutic agents.

  Molecular pharmacology 20020901

• Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma.

  Urological research 20020901

• Topotecan preceded by oxaliplatin using a 3 week schedule: a phase I study in advanced cancer patients.

  European journal of cancer (Oxford, England : 1990) 20020901

• SWOG-9510: evaluation of topotecan in hormone refractory prostate cancer: a Southwest Oncology Group study.

  The Prostate 20020901

• Combined effect of topotecan and irradiation on the survival and the induction of chromosome aberrations in vitro.

  Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20020901

• VIII International Conference on malignant lymphoma. June 12-15, 2002 Lugano, Switzerland.

  Clinical lymphoma 20020901

• Carboplatin and topotecan combination and myelosuppression.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020815

• Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.

  European journal of cancer (Oxford, England : 1990) 20020801

• Phase I trial of topotecan plus vinorelbine with/without filgrastim (G-CSF) in patients with refractory malignancies.

  American journal of clinical oncology 20020801

• Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway.

  Cancer research 20020801

• Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation.

  Anti-cancer drugs 20020801

• Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study.

  Leukemia & lymphoma 20020801

• [Gemicitabine in the treatment of epithelial ovarian cancer].

  Bulletin du cancer 20020801

• Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513.

  International journal of radiation oncology, biology, physics 20020715

• Boosting bioavailability of topotecan: what do we gain?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020701

• Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020701

• Urinary and fecal excretion of topotecan in patients with malignant solid tumours.

  Cancer chemotherapy and pharmacology 20020701

• Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance.

  International journal of cancer 20020701

• Topotecan-induced celluitis-like fixed drug eruption.

  Journal of the European Academy of Dermatology and Venereology : JEADV 20020701

• Topotecan is anti-angiogenic in experimental hepatoblastoma.

  Journal of pediatric surgery 20020601

• Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors.

  Journal of cancer research and clinical oncology 20020601

• Phase I studies of nogitecan hydrochloride for Japanese.

  International journal of clinical oncology 20020601

• Troxacitabine-based therapy of refractory leukemia.

  Expert review of anticancer therapy 20020601

• Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.

  Current cancer drug targets 20020601

• C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.

  Molecular cancer therapeutics 20020601

• Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice.

  British journal of cancer 20020520

• Intraperitoneal adenovirus-mediated suicide gene therapy in combination with either topotecan or paclitaxel in nude mice with human ovarian cancer.

  Cancer gene therapy 20020501

• Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer.

  Gynecologic oncology 20020501

• Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.

  Cancer chemotherapy and pharmacology 20020501

• Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors.

  Clinical pharmacology and therapeutics 20020501

• No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients.

  European journal of clinical pharmacology 20020501

• Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.

  Cancer 20020501

• [A case of recurrent small cell lung cancer with symptoms improved by nogitecan hydrochloride].

  Gan to kagaku ryoho. Cancer & chemotherapy 20020501

• [Nogitecan hydrochloride].

  Nihon rinsho. Japanese journal of clinical medicine 20020501

• Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels.

  Leukemia & lymphoma 20020501

• [Early results of topotecan therapy in patients with recurrent ovarian cancer].

  Orvosi hetilap 20020421

• Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.

  Gynecologic oncology 20020401

• Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer.

  Gynecologic oncology 20020401

• Phase I study of topotecan and radiation therapy in advanced cervical cancer.

  Gynecologic oncology 20020401

• Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma.

  Cancer 20020401

• Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients.

  American journal of clinical oncology 20020401

• Recurrent ovarian cancer as chronic disease.

  Oncology (Williston Park, N.Y.) 20020401

• Epithelial ovarian cancer.

  Current treatment options in oncology 20020401

• [Killing and proapoptotic effects of topoisomerase I inhibitor on K562 cells].

  Ai zheng = Aizheng = Chinese journal of cancer 20020401

• [Phase II clinical study of topotecan hydrochloride in patients with recurrent advanced ovarian cancer].

  Ai zheng = Aizheng = Chinese journal of cancer 20020401

• Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

  Molecular cancer therapeutics 20020401

• Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020315

• Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020315

• Chfr regulates a mitotic stress pathway through its RING-finger domain with ubiquitin ligase activity.

  Cancer research 20020315

• Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells.

  Cytokine 20020307

• Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of the PI3K-Akt signaling pathway.

  International journal of cancer 20020301

• Chemotherapy and pregnancy.

  Clinical obstetrics and gynecology 20020301

• Distinct response of experimental neuroblastoma to combination antiangiogenic strategies.

  Journal of pediatric surgery 20020301

• Comparison of camptothecin derivatives presently in clinical trials: genotoxic potency and mitotic recombination.

  Mutagenesis 20020301

• A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020301

• Topotecan and the development of scleroderma or a scleroderma-like illness.

  Arthritis and rheumatism 20020301

• Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance.

  Japanese journal of cancer research : Gann 20020301

• Preclinical and phase I study of oxaliplatin and topotecan in combination in human cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20020301

• Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules.

  Annals of oncology : official journal of the European Society for Medical Oncology 20020301

• Neutrophilic eccrine hidradenitis secondary to topotecan.

  The Journal of dermatological treatment 20020301

• Differential response of tumor cells and normal fibroblasts to fractionated combined treatment with topotecan and ionizing radiation.

  International journal of radiation biology 20020201

• Phase I/II clinical trial of concurrent radiochemotherapy in combination with topotecan for the treatment of brain metastases.

  European journal of cancer (Oxford, England : 1990) 20020201

• Individual adaptive dosing of topotecan in ovarian cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020201

• The role of gemcitabine-based doublets in the management of ovarian carcinoma.

  Seminars in oncology 20020201

• Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182).

  Seminars in oncology 20020201

• [Developed new agents for lung cancer].

  Nihon Geka Gakkai zasshi 20020201

• Clinical trials using irinotecan.

  Journal of pediatric hematology/oncology 20020201

• Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942.

  Journal of pediatric hematology/oncology 20020201

• Phase II trial of topotecan by continuous infusion in patients with advanced soft tissue sarcomas, a SWOG study. Southwest Oncology Group.

  Investigational new drugs 20020201

• Nucleolar delocalization of human topoisomerase I in response to topotecan correlates with sumoylation of the protein.

  The Journal of biological chemistry 20020125

• Cell-based assays for identification of novel double-strand break-inducing agents.

  Journal of the National Cancer Institute 20020116

• X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance.

  Cancer research 20020115

• S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function.

  The Journal of biological chemistry 20020111

• Determination of topotecan in human whole blood and unwashed erythrocytes by high-performance liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020105

• The use of oral cytotoxic and cytostatic drugs in cancer treatment.

  European journal of cancer (Oxford, England : 1990) 20020101

• A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer.

  European journal of cancer (Oxford, England : 1990) 20020101

• Phase I study of combination topotecan and carboplatin in pediatric solid tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020101

• Histologic and immunohistochemical analysis of tissue response to adenovirus-mediated herpes simplex thymidine kinase gene therapy of ovarian cancer.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20020101

• A phase II study of topotecan in non-Hodgkin's lymphoma: an Ohio State University phase II research consortium study.

  Cancer investigation 20020101

• Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel-cisplatin-topotecan in a phase I study.

  Anti-cancer drugs 20020101

• Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer.

  Drugs & aging 20020101

• New approaches to the treatment of myelodysplasia.

  The oncologist 20020101

• An HIV treatment the world may never see.

  Positively aware : the monthly journal of the Test Positive Aware Network 20020101

• Effect of topotecan infusion duration on hematologic toxicity in recurrent ovarian carcinoma.

  Medical oncology (Northwood, London, England) 20020101

• [Interaction of topotecan, DNA topoisomerase I inhibitor, with double-stranded polydeoxyribonucleotides. III. Binding at the minor groove].

  Molekuliarnaia biologiia 20020101

• Topotecan in the treatment of refractory neuroblastoma and other malignant tumors in childhood - a phase-II-study.

  Klinische Padiatrie 20020101

• Impact of topotecan-based chemotherapy on the immune system of advanced ovarian cancer patients: an immunophenotypic study.

  Oncology reports 20020101

• Weekly topotecan: an alternative to topotecan's standard daily x 5 schedule?

  The oncologist 20020101

• Phase I study of sequential administration of topotecan and 5-fluorouracil in patients with advanced malignancies.

  Cancer investigation 20020101

• The role of topotecan as second-line therapy in patients with recurrent ovarian cancer.

  European journal of gynaecological oncology 20020101

• Update on the role of topotecan in the treatment of recurrent ovarian cancer.

  The oncologist 20020101

• Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer.

  The oncologist 20020101

• Update on the treatment of cervical and uterine carcinoma: focus on topotecan.

  The oncologist 20020101

• Emerging role of topotecan in front-line treatment of carcinoma of the ovary.

  The oncologist 20020101

• Intralesional topotecan in advanced ovarian cancer: a clinical report, based on a preclinical study.

  Oncology reports 20020101

• [Interaction of topotecan, DNA topoisomerase I inhibitor, with double-stranded polydeoxyribonucleotides. 4. Topotecan binds preferably to the GC base pairs of DNA].

  Molekuliarnaia biologiia 20020101

• Oral cytotoxic drugs.

  I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.] 20020101

• Early detection and successful treatment of drug-induced pneumonitis with corticosteroids.

  Cancer investigation 20020101

• A dose-escalation study of weekly topotecan, cisplatin, and gemcitabine front-line therapy in patients with inoperable non-small cell lung cancer.

  The oncologist 20020101

• [4th National Conference of the Italian Association of Medical Oncology. From research to clinical practice: the role of topotecan in oncology].

  Tumori 20020101

• Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.

  Blood 20011215

• Model for time dependency of cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action.

  The Journal of pharmacology and experimental therapeutics 20011201

• Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer.

  European journal of cancer (Oxford, England : 1990) 20011201

• Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor.

  Journal of pediatric surgery 20011201

• A phase I/II study of topotecan in combination with carboplatin in recurrent epithelial ovarian cancer.

  Gynecologic oncology 20011201

• Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up.

  Gynecologic oncology 20011201

• Treatment of advanced ovarian cancer.

  European journal of cancer (Oxford, England : 1990) 20011201

• Phase III data on Caelyx in ovarian cancer.

  European journal of cancer (Oxford, England : 1990) 20011201

• Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20011201

• Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.

  American journal of hematology 20011201

• Acute toxicity and changes in quality of life during a combined radio-chemotherapy of glioblastomas with topotecan (Hycamtin).

  Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 20011201

• Quantitation of camptothecin and related compounds.

  Journal of chromatography. B, Biomedical sciences and applications 20011125

• Design and optimization of 20-O-linked camptothecin glycoconjugates as anticancer agents.

  Journal of medicinal chemistry 20011122

• Efficacy of topotecan treatment on an experimental model of transient evoked otoacoustic emissions.

  International journal of pediatric otorhinolaryngology 20011101

• Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer.

  Gynecologic oncology 20011101

• A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients.

  Gynecologic oncology 20011101

• A phase I and pharmacokinetic study of intraperitoneal topotecan.

  British journal of cancer 20011101

• Successful therapy of subcutaneously growing human hepatoblastoma xenografts with topotecan.

  Medical and pediatric oncology 20011101

• A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients.

  Annals of oncology : official journal of the European Society for Medical Oncology 20011101

• [Single topotecan or in combination with other chemotherapeutic agents for 18 recurrent advanced ovarian cancer patients].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20011101

• A new method to evaluate in vitro myelotoxicity of antitumour agents in the first steps of drug development.

  Pharmacology & toxicology 20011101

• High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.

  Cancer 20011015

• Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children's oncology group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20011015

• A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20011001

• Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20011001

• Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20011001

• A new case of isolated del(12)(q15q22) in myelodysplastic syndrome.

  Cancer genetics and cytogenetics 20011001

• Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.

  Bone marrow transplantation 20011001

• Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer.

  British journal of cancer 20011001

• Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.

  Cancer research 20010915

• High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.

  Gynecologic oncology 20010901

• Therapeutic options for acute myelogenous leukemia.

  Cancer 20010901

• A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors.

  Cancer 20010901

• Synergistic interaction between topotecan and microtubule-interfering agents.

  Cancer chemotherapy and pharmacology 20010901

• Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults.

  Bone marrow transplantation 20010901

• Topotecan-filgrastim combination is an effective regimen for mobilizing peripheral blood stem cells.

  Bone marrow transplantation 20010901

• A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line.

  Cancer research 20010815

• Clonal heterogeneity of p53 mutations in ovarian cancer.

  International journal of oncology 20010801

• Phase I clinical trial of weekly combined topotecan and irinotecan.

  American journal of clinical oncology 20010801

• Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor.

  Journal of pediatric surgery 20010801

• Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010801

• Pharmacodynamic model of topotecan-induced time course of neutropenia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010801

• Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines.

  International journal of cancer 20010715

• Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010715

• A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors.

  Cancer 20010715

• Topotecan selectively enhances the radioresponse of human small-cell lung carcinoma and glioblastoma multiforme xenografts in nude mice.

  International journal of radiation oncology, biology, physics 20010701

• UCN-01 dose-dependent inhibition of normal hyperproliferative cells in mice.

  International journal of oncology 20010701

• Effective dosing of topotecan with carboplatin in relapsed ovarian cancer: a phase I/II study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010701

• Topoisomerase I inhibitors in the treatment of head and neck cancer.

  Oncology (Williston Park, N.Y.) 20010701

• Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010701

• Sodium phenylbutyrate induces apoptosis in human retinoblastoma Y79 cells: the effect of combined treatment with the topoisomerase I-inhibitor topotecan.

  International journal of oncology 20010601

• Temporary reversal by topotecan of marked insulin resistance in a patient with myelodysplastic syndrome: case report and possible mechanism for tumor necrosis factor alpha (TNF-alpha)-induced insulin resistance.

  American journal of clinical oncology 20010601

• Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study.

  Onkologie 20010601

• Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines.

  Cancer chemotherapy and pharmacology 20010601

• Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010515

• Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer.

  Cancer research 20010515

• Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer.

  Lung cancer (Amsterdam, Netherlands) 20010501

• Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.

  Gynecologic oncology 20010501

• Phase II trial of topotecan, carboplatin, and paclitaxel as front-line therapy in suboptimal advanced epithelial ovarian cancer.

  Gynecologic oncology 20010501

• A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study.

  British journal of cancer 20010501

• A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study.

  Gynecologic oncology 20010501

• Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.

  Journal of pediatric hematology/oncology 20010501

• Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010415

• A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma.

  Blood 20010401

• Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010401

• Determination of topotecan by ELISA.

  Biological & pharmaceutical bulletin 20010401

• Radiosensitization of tumor-targeted radioimmunotherapy with prolonged topotecan infusion in human breast cancer xenografts.

  Cancer research 20010401

• Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer.

  British journal of cancer 20010401

• The association of topotecan and cytarabine in the treatment of secondary or relapsed acute myeloid leukemia.

  Haematologica 20010401

• Antitumor activity of XR5944, a novel and potent topoisomerase poison.

  Anti-cancer drugs 20010401

• New agents for induction and postremission therapy of acute myeloid leukemia.

  Leukemia 20010401

• Phase I dose escalation study of topotecan combined with alternating schedules of paclitaxel and carboplatin in advanced solid tumors.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010401

• Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer: a review of the Sarah Cannon Cancer Center experience.

  Seminars in oncology 20010401

• Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010315

• Carrier and dose effects on the pharmacokinetics of T-0128, a camptothecin analogue-carboxymethyl dextran conjugate, in non-tumor- and tumor-bearing rats.

  Journal of controlled release : official journal of the Controlled Release Society 20010312

• Development, characterization and therapy of a disseminated model of childhood neuroblastoma in SCID mice.

  Cancer chemotherapy and pharmacology 20010301

• Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues.

  Expert opinion on pharmacotherapy 20010301

• [Evaluation of quality of life in patients with advanced colorectal cancer treated with topotecan].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20010301

• [Clinical study of topotecan in the treatment of small cell lung cancer and recurrent ovarian cancer].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20010301

• Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group Trial 9507.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010215

• Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010215

• Topotecan concomitant with primary brachytherapy radiation in patients with cervical carcinoma: a phase I trial.

  Gynecologic oncology 20010201

• Evaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomerase-DNA complex formation with clinical response.

  Cancer 20010201

• P73a overexpression is associated with resistance to treatment with DNA-damaging agents in a human ovarian cancer cell line.

  Cancer research 20010201

• Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous carcinoma of the head and neck: an Eastern Cooperative Oncology Group Trial (E3393).

  American journal of clinical oncology 20010201

• Clear cell carcinoma of the ovary: a remarkable case.

  American journal of clinical oncology 20010201

• Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer.

  Japanese journal of clinical oncology 20010201

• Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage.

  European journal of pharmacology 20010119

• The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.

  Cancer research 20010115

• ICE bioassay. Isolating in vivo complexes of enzyme to DNA.

  Methods in molecular biology (Clifton, N.J.) 20010101

• Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010101

• Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel.

  Gynecologic oncology 20010101

• Prevention of human smooth muscle cell proliferation without induction of apoptosis by the topoisomerase I inhibitor topotecan.

  Biochemical pharmacology 20010101

• Fludarabine, cytarabine and topotecan (FLAT) as induction therapy for acute myeloid leukemia in the elderly: a preliminary report.

  Haematologica 20010101

• Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer.

  Oncology 20010101

• Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction.

  Cancer chemotherapy and pharmacology 20010101

• Treatment of extensive stage small cell lung cancer.

  Cancer treatment and research 20010101

• The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010101

• Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer.

  Cancer chemotherapy and pharmacology 20010101

• [Interaction of topotecan--a DNA topoisomerase inhibitor--with dual-stranded polydeoxyribonucleotides. I. Dimerization of topotecan in solution].

  Molekuliarnaia biologiia 20010101

• [Interaction of topotecan--a DNA topoisomerase I inhibitor--with dual-stranded polydeoxyribonucleotides. II. Formation of a complex containing several DNA molecules in the presence of topotecan].

  Molekuliarnaia biologiia 20010101

• A phase I-II trial of topotecan and gemcitabine in patients with previously treated, advanced non-small cell lung cancer (LOA-3).

  Cancer investigation 20010101

• Overview of the treatment of infant central nervous system tumors: medulloblastoma as a model.

  Journal of pediatric hematology/oncology 20010101

• Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20010101

• Phase I and pharmacologic study of sequential topotecan, carboplatin, and etoposide.

  Lung cancer (Amsterdam, Netherlands) 20010101

• Novel therapies in lung cancer management. An update on the role of topotecan.

  Oncology 20010101

• New advances in lung cancer chemotherapy: topotecan and the role of topoisomerase I inhibitors.

  Oncology 20010101

• A phase I trial of a 5-day schedule of intravenous topotecan and etoposide in previously untreated patients with small-cell lung cancer.

  Oncology 20010101

• Feasibility of oral topotecan plus intravenous paclitaxel in advanced non-small-cell lung cancer.

  Oncology 20010101

• Is cisplatin required for the treatment of non-small-cell lung cancer? Experience and preliminary results of a phase I/II trial with topotecan and vinorelbine.

  Oncology 20010101

• Feasibility of oral topotecan in previously untreated patients with small-cell lung cancer ineligible for standard therapy.

  Oncology 20010101

• Preliminary results of combined therapy with topotecan and carboplatin in advanced non-small-cell lung cancer.

  Oncology 20010101

• Future role of topotecan in the treatment of lung cancer.

  Oncology 20010101

• Intravenous bolus topotecan in patients with myelodysplastic syndrome.

  Leukemia & lymphoma 20010101

• A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.

  Health technology assessment (Winchester, England) 20010101

• A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.

  Oncology 20010101

• Serous papillary adenocarcinomas of the ovary display heterogeneity in their response to chemotherapy.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20010101

• The development of camptothecin analogs in childhood cancers.

  The oncologist 20010101

• Topotecan (Hycamtin) responsiveness in human renal carcinoma cell lines of the clear cell and papillary types.

  Anticancer research 20010101

• Long time therapy with topotecan in patients with recurrence of ovarian carcinoma.

  Anticancer research 20010101

• Effect of prechemotherapy filgrastim on the bone marrow toxicity of topotecan.

  European journal of gynaecological oncology 20010101

• Nursing considerations for managing topotecan-related hematologic side effects.

  Clinical journal of oncology nursing 20010101

• [3rd National Congress of Medical Oncology. Issues in Gynecologic Oncology. Naples, November 7, 2000].

  Tumori 20010101

• Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study.

  American journal of clinical oncology 20000801

• Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20000701

• Phase II study of oral topotecan in advanced non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20000301

• An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage.

  Cancer research 20000201

• Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan.

  Leukemia 20000101

• Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.

  Cancer research 19991201

• Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience.

  Oncology 19990101

• [Topotecan: a new field of use].

  Tumori 19990101

• Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer.

  Anti-cancer drugs 19980601

• Topotecan inhibits human immunodeficiency virus type 1 infection through a topoisomerase-independent mechanism in a cell line with altered topoisomerase I.

  Antimicrobial agents and chemotherapy 19970501

• An overview of the clinical pharmacology of topotecan.

  Seminars in oncology 19970201

• Phase II trial to topotecan in hepatocellular carcinoma: a Southwest Oncology Group study.

  Investigational new drugs 19970101

• Clinical pharmacokinetics of topotecan.

  Clinical pharmacokinetics 19960801

• Synthesis, topoisomerase I inhibitory activity, and in vivo evaluation of 11-azacamptothecin analogs.

  Journal of medicinal chemistry 19950331

• Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.

  Cancer research 19930615

• Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication.

  Proceedings of the National Academy of Sciences of the United States of America 19930301